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INVESTIGATION OF THE ROLE OF THE SCAFFOLD PROTEIN SHC
IN ERK SIGNALING

Kin Man Suen, B.Sc.

Advisor Professor: John E. Ladbury, Ph. D.
Cells respond to environmental changes by converting extracellular signals into
intracellular events. Scaffolding proteins play important roles in generating specificity in

intracellular signaling through the combinatorial use of protein domains and
posttranslational modifications.

Using the scaffold protein Shc (Src-homology collagen-

like) as a model system, we explored novel mechanisms whereby this class of protein
shapes signaling output. In the present work, we focused on the role of Shc in the MAP

kinase Erk signaling both prior to and post -growth factor stimulation. Prior to growth
factor stimulation, we found Erk to be a direct interacting partner of Shc. The two proteins

associate through a non-canonical interface. This interaction blocks the phosphorylation

of Erk and restricts its nuclear translocation. Post -growth factor stimulation, Erk is

released from Shc through an allosteric mechanism facilitated by the binding between Shc
and the activated growth factor receptor. Furthermore, fully activated Erk phosphorylates

Shc on three threonine residues. These phosphorylated residues on Shc subsequently
serve as platforms to mediate both a positive feedforward loop in prolonging Erk activity
and crosstalk with Akt signaling through protein recruitment.
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Chapter 1

Introduction

1.1 Signal Transduction
The ability for cells to respond to extracellular cues is critical to the normal

development of an organism. Cells respond to environmental changes by converting
extracellular events into intracellular signals. This process requires the detection of
extracellular cues. When these extracellular ligands, for example growth factors and

amino acids, cannot freely diffuse across the plasma membrane due to the membrane
barrier, the signal reception is mediated by transmembrane proteins.

A number of

transmembrane protein families exist, for example receptor tyrosine kinases (RTKs), G-

protein-coupled receptors (GPCRs), ion channels and transporters [1,2,3]. The interaction

of the extracellular ligands with their cognate TM receptors in turn dictates specific

cellular outcomes. However, how these interactions can be transmitted in the intracellular

environment into specific cellular outcomes is not obvious. This is because different TM

receptors often use the same downstream signaling cascades.

Hence, although

extracellular ligands are highly specific in which TM receptors they interact with, the

protein-protein interactions that are mediated by the TM receptors within cells do not
confer sufficient specificity in generating a particular biological outcome. For example,
stimulation of the rat pheochromocytoma cell line PC12 with epidermal growth factor
(EGF) leads to cell proliferation, whereas stimulation using nerve growth factor (NGF)

leads to differentiation of the PC12 cells into neuron-like cells with neurites. Distinct
1

signaling outcomes from the two different ligand-receptor pairs suggest different

downstream signaling components were used. Surprisingly, however, examination of the
downstream signaling from these two receptors reveals that the same signaling cascade,

the Erk (extracellular-regulated kinase) cascade, is responsible for the phenotypes and
that the determining factor for these two very different outcomes is the duration of its
activation [4,5]. How then is the activity of Erk, or other signaling enzyme, regulated
temporally and how does this translate into phenotypic outcome?

Much progress has been made in the understanding of how specificity in

intracellular signaling is conferred. It became apparent early-on that unidirectional linear

pathways acting in isolation cannot support the diverse signaling output required in
development.

Rather, cells utilize feedback loops within a pathway and cross talks

between pathways to build signaling networks in order to generate complex biological

processes [6,7,8]. Two strategies are used to build these regulatory mechanisms. The first
is the modular arrangement of folded domain structures in proteins. Each type of protein
domain contains a certain polypeptide fold that enables it to recognize specific motifs.

Some protein domains recognize covalently modified amino acids, such as the Src
Homology 2 (SH2) domains binding to phosphorylated tyrosine residues. Others bind to

unmodified motifs, as in the case of SH3 domains engaging Pro-X-X-Pro sequences [9]. The
second strategy is posttranslational modifications (PTMs). PTMs provide stable and yet

reversible effects on proteins such that they are ideal molecular switches

[10,11,12,13,14,15,16]. A variety of PTMs have been described, each exploiting specific
chemical properties on certain amino acids. For example, a phosphate moiety is added to

the hydroxyl group on serine, threonine or tyrosine residues effectively changing its

charge and size, binding interactions and thus function, such as activating / inactivating
2

protein function [17]. For example, Erk2 is inactive prior to phosphorylation on T183 and
Y185. Phosphorylation on these two residues causes Erk2 to adopt an active conformation

by rearranging both the ATP- and substrate-binding sites. Many proteins possess both
multiple domains (strategy #1) and PTMs (strategy # 2), which lead to a combinatorial
effect in protein recruitment and enable dynamic assembly of complexes that modulate
biological outcomes [14,18,19].

Scaffolding/adaptor proteins, a term typically reserved for polypeptides that do not

possess any enzymatic activity and whose major function is to facilitate the formation of

protein complexes, utilize both of these strategies to direct the flow of signaling
information (Figure 1) [20,21].

Figure 1. Scaffold proteins facilitate the formation of protein complexes to regulate
signaling outcome. (A) and (B) Scaffold proteins usually contain multiple domains. Some

domains bind to unmodified peptides, such as the SH3 domain binding to Pro-X-X-Pro

motifs. Other domains interact with modified peptides, such as SH2 domain binding to

motifs containing phosphorylated-tyrosine. (C) Scaffold proteins are post-translationally
modified to form binding sites for other proteins. For example, a scaffold protein can be
phosphorylated on a tyrosine residue, which recruits SH2 domain-containing proteins.

3

Recent advances in high-throughput techniques offer a glimpse into the complex

role performed by scaffolding/adaptor proteins in signaling. For example, growth factor

receptor bound protein 2 (Grb2) contains a Src-homology 2 (SH2) domain flanked by two
Src-homology 3 (SH3) domains. By associating with son of sevenless (Sos) through its N-

terminal SH3 domain and fibroblast growth factor (FGF) receptor via its SH2 domain, it
drives embryonic stem cell into the primitive endoderm lineage. [22]. Furthermore,

manipulation of the SH2 domain such that the affinity for phosphotyrosine-containing
motifs leads is changed, which in turn leads to a change in its protein recruitment profile

and consequently the expression of a pluripotency factor [23]. Another well-characterized

example is kinase suppressor of Ras (KSR).

By associating with the three kinases

simultaneously in the Erk cascade, KSR enables efficient phosphorylation between the

components by juxtaposing them close to each other and eliminating the need for
diffusion.

The final kinase of the Erk cascade, once activated by its kinase Mek,

phosphorylates KSR to block its binding to Raf, the first member of the cascade, thereby
terminating the signal [24].

This work focuses on the Src-homology collagen-like (Shc) scaffolding protein to

explore novel mechanisms whereby scaffolding proteins regulate signaling events. Shc

exemplifies how scaffold proteins shape signaling output. Shc has a large repertoire of
protein binding partners, whose functions span diverse cellular processes [25,26].

Furthermore, in addition to its existing protein-protein interacting domains, Shc is also
post-translationally modified at multiple sites. Post-translational modification of Shc

creates transient binding motifs that in turn provide additional specificities in protein
recruitment [27]. The many contributions of Shc in a large array of cellular processes are
4

discussed in the following sections, with emphasis on the molecular mechanisms involved
where they are known.
1.2 Shc - General
The first member of the Shc family was identified in a cDNA library screen for SH2-

domain-containing proteins in 1992 [28]. Since then, four Shc genes have been identified

in mammals, which are classified according to their sequence of discovery as ShcA, ShcB,

ShcC and ShcD [28,29,30,31,32]. The four Shc genes are differentially expressed in adult
tissues: ShcA is ubiquitously expressed except in the nervous system; ShcB and ShcC are
predominately expressed in the nervous system [29]; and ShcD is primarily expressed in

the brain and skeletal muscle [31]. Despite difference in their primary sequences, all four

of the Shc proteins consist of the core architecture of an N-terminal phosphotyrosinebinding (PTB) domain, a central collagen-homology 1 (CH1) domain and a C-terminal Src

Homology 2 (SH2) domain. Additionally, some members of the family contain a collagenhomology 2 (CH2) domain N-terminal to the PTB domain (Figure 2). The PTB and SH2

domains are capable of binding to phosphorylated-tyrosines, whereas the CH1 and CH2
domains are phosphorylated on serine, threonine and tyrosine residues to form binding
sites to recruit other proteins.

Figure 2. Shc protein architecture

5

1.3 ShcA

1.3.1 Isoforms
The ShcA gene produces three protein products. The p52 and p46 isoforms are

generated by alternative start codons, while the p66 transcript is alternatively-spliced to
contain an additional CH2 domain [33]. The p66 isoform was noted for its absence in

hematopoietic cell lines [28] and was later found that its differential expression pattern is

owed to epigenetic regulation through the use of an alternative promoter [34]. Although
the core domains of the three ShcA isoforms share the same sequences, differences in
downstream signaling involving these domains have been observed (discussed below),
suggesting the N-terminal sequence interferes with the core domain functions.

1.3.2 Domain architecture
The phosphotyrosine-binding (PTB) and Src-homology 2 (SH2) domains form well-

folded modules, whereas the collagen-homolgy 1 and 2 (CH1 and CH2) domains lack
tertiary structures. Each domain is responsible for interacting with a distinct array of
proteins, enabling Shc to coordinate multiple signaling events.

1.3.2.1 PTB domain
The PTB domain is composed of three α-helices, one of which at each N- and C-

terminal ends, and two β-sheets that are placed orthogonally [35]. It is in a relatively
disordered state which folds to form the phosphobinding pocket upon binding to phospho6

peptides [36].

Binding studies and structure of the PTB domain in complex with a

phospho-peptide show that a β-turn on the peptide is critical to phosphotyrosine binding
to the protein, conferring binding specificity of Asn-Pro-X-pTyr (NPXpY; where X is any
reside), due to the ability of Asn-Pro to form a β-turn (Figure 3) [35,37,38]. The PTB

domain has been shown to bind to a large array of receptor (See 1.4.1.1) and cytosolic

kinases via their phosphorylated-tyrosine motifs [27]. While most of the binding partners
for this domain are mediated by phosphorylated tyrosines, a few proteins have been
reported to interact with the PTB domain independent of phosphorylation [39,40,41,42].

For example, the cytoskeletal protein IQGAP1 was found to interact with residues in the
PTB domain outside of the phosphotyrosine-binding pocket [39].

The protein-tyrosine

phosphatase-PEST (PTP-PEST) has also been shown to associate with the PTB domain via

a Asn-Pro-Leu-His motif [40] and interestingly the PTP-PEST peptide was able to inhibit
IQGAP1 binding, suggesting that the binding sites for these two proteins overlap to some

extend but not completely. The tertiary structure of the PTB domain also resembles the

Pleckstrin-homology (PH) domain [43], which prompted the characterization of the
protein’s phospholipid-binding ability. It was shown to bind to phosphatidylinositol 4,5-

bisphosphate (PtdIns(4,5)P2) using residues distinct from the ones utilized for

phosphotyrosine-binding [35,44].
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Figure 3. Structure of ShcPTB domain in complex with TrkA peptide (PDB: 1SHC).
The PTB domain of Shc is in green. TrkA peptide is in wheat.

The PTB domain is

composed of three α-helices, one of which at each N- and C-terminal ends, and two β-

sheets that are placed orthogonally. Asn-Pro forms a β-turn on the peptide, which is
circled in black. This β-turn is important to the correct positioning of the peptide to the
PTB domain.

1.3.2.2 CH1 domain
The CH1 domain contains an unusually high number of proline and glycine residues

much like a collagen protein primary sequence [45]. However, it lacks the proline-glycine

regular repeats that are required for the formation of helices and instead forms a

disordered region in the Shc protein. The main function for this domain delineated thus
8

far is in the activation of mitogenic signaling to recruit the SH2 domain of Grb2.

Recruitment of Grb2 is mediated by the phosphorylation of Y239, Y240 and Y317 on Shc

[46,47].

Additional phosphorylation sites, T214 and S335 in this region have been

identified recently via proteomic analysis of Rat1 cells that were trigged by EGF. However,

the functions of this threonine/serine phosphorylation have not yet been characterized

[26]. In addition to the phosphorylation sites, the CH domain contains multiple Pro-X-XPro motifs and it has been shown to associate with the Src, Fyn and Lyn SH3 domains [48].
However, physiological roles for these interactions have not been described.

1.3.2.3 SH2 domain
The SH2 domain of Shc consists mainly of a central anti-parallel β-sheet flanked by

two α-helices (Figure 4) [49]. The SH2 domain recognizes tyrosyl phosphopeptides with a
Ile/Leu/Met as the third residue C-terminal of the phosphotyrosine (pY+3) position is
preferred [50]. A smaller set of binding partners have been reported for the SH2 domain

compared with the PTB domain. Given the fact that SH2 domains in general are capable of
interacting with a large number of proteins as in the case of PTB domains, it is likely that

many of the ShcSH2 binding partners are still uncharacterized. The T-cell receptor zetachain interacts with the SH2 domain in a phosphotyrosine dependent manner [51], while

SHCBP1 was shown to bind independent of tyrosine phosphorylation [52]. However, the
physiological relevance of the Shc-SHCBP1 interaction has not been determined.
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Figure 4. Structure of ShcSH2 domain in complex with TCR peptide (PDB: 1TCE).
The SH2 domain consists of a central anti-parallel β-sheet flanked by two α-helices. A Leu

in the pY+3 position on the TCR peptide confers specificity to the domain-peptide
interaction.

1.3.2.4 CH2 domain
Only the p66shc isoform possesses a CH2 domain at its N-terminal. Similar to the

CH1 domain, the CH2 domain is rich in proline and glycine residues.

The best

characterized feature of the CH2 domain is S36, which is phosphorylated under oxidative

stress [53] by protein kinase C. Phosphorylation of S36 recruits the peptidyl-prolyl cis-

trans isomerase NIMA interacting 1 protein (Pin1), which leads to apoptosis (see 1.4.4)

[54].
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1.3.2.5 Cytochrome C binding region
The linker region between the CH2 and PTB domains has been found to function as

a redox center, by binding to and oxidizing cytochrome C via E132 and E133, and W134

(See 1.4.4) [55].

1.4 ShcA in signaling

1.4.1 Mitogen-activated protein kinase (MAPK) signaling

1.4.1.1 Extracellular signal-regulated kinase (Erk) pathway
The p52 and p46 isoforms of Shc act downstream of most RTKs to activate Erk

signaling [27,56]. Upon activation of the receptor by a cognate ligand, the receptor
undergoes autophosphorylation on its tyrosine residues [1].

Shc binds to the

phoshotyrosine residues on the receptor via its PTB domain, which in turn leads to the
phosphorylation on Y239, Y240 and Y317 in its CH1 domain [46,47,57].

These

phosphorylated residues recruit Grb2, which is constitutively bound to the guanine

nucleotide exchange factor, Sos [58,59]. Sos activates the small GTPase Ras by promoting
GDP-GTP exchange. One of Ras’ effectors is the MAPK-kinase-kinase Raf, whose activation

leads to phosphorylation of Mek. Mek in turn phosphorylates and activates the terminal
kinase Erk (Figure 5) [60].

Intriguingly, the p66 isoform has been reported to

downregulate Erk signaling in EGF [33] and cytokine signaling [61], even though it is able
to bind to the receptor and Grb2 [62].

How p66 Shc regulates Erk signaling differently

from the p52 and p46 isoforms is unclear, although it is likely that the differences in their
11

N-terminal sequences may play a role.

p52 Shc also leads to the activation of Erk

downstream of T-cell receptor activation, although its phosphorylation is carried out by

the cytosolic kinase Lck [63].

Figure 5. Canonical role of p52/p46 Shc in the activation of Erk pathway. RTK
autophosphorylates on its tyrosine residues upon the binding of ligand.

These

phosphorylated tyrosines recruit Shc via the Shc PTB domain. Shc is subsequently
phosphorylated by the receptor on Y239/240 and Y317. Phosphorylated Shc then recruits

the Grb2/Sos complex. Sos activates the small GTPase Ras, which leads to the activation of
the Erk cascade through the sequential phosphorylation of the three kinase members.

Activated Erk phosphorylates a range of substrates which leads to various biological
outcomes, such as proliferation and differentiation.
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1.4.1.2 c-Jun N-terminal kinase pathway
Two studies in the C. elegans model system identified MEK-1, the MAPK kinase for

the JNK pathway, to be a binding partner for SHC-1, the homolog of mammalian p52 Shc.

While both studies showed that SHC-1 confers resistance to stress when the animals are

exposed to heavy metal and that this response is MEK-1-dependent, Mizuno et. al. and
Neumann-Haefelin et. al. attributed the phenotype to be mediated by KGB-1 (JNK-like

kinase) and JNK-1, respectively [64,65]. These studies suggest that MEK-1 is able to
activate multiple members of the JNK family. Although data showing conservation of the
Shc-MEK-JNK pathway in higher vertebrates is lacking, a study in T-cell signaling found
that tyrosine phosphorylation of p52 Shc augments JNK phosphorylation [66].

1.4.2 Phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) pathway
The Shc p52 isoform has been shown to activate PI3K signaling downstream of

insulin-like growth factor stimulation in vascular smooth muscle cells by binding to Grb2,

which then recruits the p85 subunit of PI3K. The over-expression of a Shc mutant that is
defective in Grb2-binding leads to reduced phospho-AKT level and cell migration

[67]. Two studies in cytokine signaling also support a direct role for Shc in the activation

of the PI3K pathway, although achieved via different molecular mechanisms. Barry et. al.
proposed that upon cytokine stimulation, the scaffolding protein 14-3-3 ζ is tyrosine

phosphorylated, which then recruits Shc via its SH2 domain and this interaction is
required for PI3K activation [68]. However, an earlier study by Gu et. al. carried out under

similar conditions, reported that Shc activates PI3K signaling through the recruitment of
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Gab2 and Grb2 [69], indicating that Shc is able to activate the PI3K pathway through the
independent use of two of its domains via separate mechanisms.

1.4.3 Mammalian target of rapamycin (mTOR) signaling
A recent metabolomics analysis revealed p66 Shc to be a critical regulator in

anabolic metabolism. Using p66 deficient mouse embryonic fibroblasts (MEFs), it was
shown that the abundance of a number of intermediates, such as glucose-6-phosphate, in
glycolysis is altered and that this trend can be partially reversed by inhibiting mTOR.
Thus, p66Shc inhibits anabolic metabolism via mTOR signaling [70].

1.4.4 Redox signaling
Migliccio et. al. first reported a role for p66Shc in oxidation stress when p66Shc

knockout mice exhibited resistance to oxidative stress and a prolonged life span. They
also showed that the phosphorylation of S36 in the CH2 domain is critical to this process
[53]. Subsequent studies established that p66Shc performs this task through multiple
mechanisms. p66Shc was shown to regulate oxidative stress induced apoptosis involving
the transcription factors Forkhead 1 and p53.

It mediates the phosphorylation and

inactivation of the Forkhead protein, whose activation in ROS-scavenger expression

promotes oxidative stress resistance [71,72]. By contrast, p53 activity stabilizes the
p66Shc protein level, thereby regulating cytochrome C release and apoptosis [73]. Giorgio
et. al. made several important observations which led to the surprising discovery that

p66Shc possesses oxidizing power. p66 Shc was shown to reside in the mitochondrial
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intermembrance space and can induce swelling of the organelle. Further dissection of how

this occurs reveals that residues 132-134 of p66Shc binds to and mediates the oxidation of
cytochrome C. This leads to the generation of reactive oxidative species and triggers
apoptosis [55]. Finer details for how p66Shc migrates in the mitochondria to carry out its

redox function were established using Pin1 knockout MEFs. Pin1 is a phosphorylationdependent prolyl isomerase. It was shown that when cells were challenged by oxidative

stress, protein-kinase C β isoform (PKCβ) is specifically activated, which leads to the

phosphorylation of S36 on p66Shc. Phosphorylated S36 recruits Pin1, which enables
p66Shc to translocate to the mitochondria [54]. An earlier study also suggested that
p66Shc is associated with the mitochondrial chaperone HSP70 such that when cells

experience oxidative stress HSP70 releases p66Shc allowing it to trigger apoptosis [74].

Thus, p66Shc seems to exist in both the cytoplasm and mitochondria prior to oxidative
stress.

Upon oxidative stress, p66Shc is either transported to the mitochondria or

released from the HSP70 inhibitory complex to induce apoptosis.

1.5 ShcA in Development

1.5.1 Cardiovascular system
Deletion of ShcA in mice is embryonically lethal and the animals die by E11.5.

Investigation into the cause of death revealed that transcription of ShcA is detectable by E9
and predominately in the cardiovascular system. A number of defects in the vascular
development were observed in Shc-deficient animals including reduced cell-to-cell
contacts and complexity in vascular architecture.
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Shc-deficient MEFs provided insights

into the molecular pathway for these defects. While Shc is not required for Erk activity

when cells were stimulated with growth factors, it sensitizes cells towards the presence

low levels of growth factors. Also mutant MEFs exhibited abnormal distribution of actin
bundles [75]. Although Shc is highly tyrosine phosphorylated in MEFs derived from E10
embryos and it potentiates Erk activity in these cells, it was however surprising that

knock-in mice expressing the ShcA Y239/240/317F mutant were viable with grossly
normal cardiovascular development. This was unexpected because the mutation of Y239

to F would prevent phosphorylation of the tyrosine residues, and this tyrosine
phosphorylation is essential for the role of ShcA in Grb2-Sos recruitment. This reflects

that not all ShcA signaling is channeled through the Grb2-Sos axis. This is also supported
by the fact that in Drosophila, while DSHC acts downstream of RTKs Torso and DER, it

lacks one of the mammalian Grb2 binding sites and that it acts in parallel to signaling
transduced via DRK, the Drosophila Grb2 [76,77].

1.5.2 Muscular tissue
Hardy et. al. generated a series of mouse models to systematically study the

contributions of the various phoshotyrosine binding modules in ShcA in development
using the cre-loxP system to generate ShcA mutants specifically in muscles. Both ShcA-null

and ShcPTB R175Q mutant (this mutation abolishes the phosphotyrosine-binding ability
of the PTB domain) mice were non-viable. Unlike the ShcA-null or the ShcPTB R175Q

mutant mice, animals harboring mutations in either the SH2 (R397K, this mutation

prevents the SH2 domain from binding to phosphotyrosine motifs) or CH1

(Y239/240/313F; Y313 in mice is equivalent to Y317 in human) domains were viable.
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However, these animals suffered from ataxia. Consistent with previous finding that p52
Shc associates with Grb2 upon ErbB3 activation in myotubes [78], the Y239/240/313F

mutant mice possess a greatly reduced number of muscle spindles, which are derived from

myotubes. This suggests that the Shc/Grb2-Sos axis is required for spindle development.

While the SH2 mutant animals had comparable number of muscle spindles, the
architecture was abnormal [79]. The differences in phenotypic outcomes among the

mutants are consistent with the fact that the three Shc domains recruit distinct sets of
proteins and can therefore mediate different biological processes.

1.5.3 Immune system
Zhang et. al. used two complementary mouse models to investigate the role of ShcA

in T-cell development. Using the lck-cre-loxP system, expression of Shc Y239/240/317F
mutant was only induced in early thymocytes.

It was found that ShcA Y239/240/317F

mutant mice have smaller thymi due to a decrease in thymocyte number. The reduction in
thymocytes was caused by an arrest at the third phase of the double-negative stage (DN3)

in which ShcA Y239/240/317F mutant specifically affects the proliferative, but not
apoptotic, signaling from pre-TCR as revealed by cell cycle analysis. Similar observations
were confirmed in lck-cre-ShcA conditional knockout mice [80]. Thus, ShcA functions in
early T-cell development requires the phosphorylation of ShcCH1. Given the role of ShcA

in the activation of Erk and the multiple functions of Erk in T-cell development including

the promotion of DN3-DN4 transition in T-cells [81], a subsequent study was carried out

using the same genetic strategy to overexpress ShcA Y239/240F mutant or ShcA Y317F
mutant in early thymocytes, and the level of Erk phosphorylation was analyzed. The
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overexpression of ShcA Y239/240F significantly diminishes phospho-Erk level to a
comparable level when cells overexpressed ShcA Y239/240/317F.

However,

overexpression of ShcA Y317F led to a comparable phospho-Erk level as in ShcA WT

animals. The same trend was observed for the total number of thymocytes. The study

revealed that Y239/240 are primarily responsible for the reduction in thymocyte number
and DN3 arrest as observed in the ShcA Y239/240/317F model. Furthermore, phosphoErk level was severely reduced in these thymocytes [82]. Hence, while the only known

function of Y239/240 and Y317is the recruitment of Grb2/Sos for the activation of Erk,

this study suggests that in the context of T-cell signaling, Y317 is not necessary for this
function. It is unclear how this differential effect of Y239/240 and Y317 occurs, or
whether Y317 is phosphorylated endogenously in T-cells.

1.5.4 Neuronal tissue
ShcA is expressed at a high level during early embryonic development in the

nervous system. Its expression declines gradually as the embryo develops, by postnatal
stages, the expression of ShcA is undetectable. Culturing of isolated embryonic neuronal

cells that were induced to differentiate show a concomitant reduction in ShcA expression.
Furthermore, ShcA mRNA is detected mainly in the proliferative zones of the brain.

Therefore, ShcA expression is highly temporally and spatially regulated during the

development of the nervous system. The timing of ShcA expression suggests that it is
required for neuroblast proliferation and downregulated for differentiation to proceed.
Stimulating the cerebral ventricle system of mouse embryos with EGF injections showed

that p46 and p52, but not p66 Shc, are tyrosine-phosphorylated and bind to EGFR as well
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as Grb2 [83]. Again, this suggests that the N-terminal sequence in p66Shc interferes with
functions of the other domains in the ShcA protein. Studies in mouse models show that
ShcA acts through multiple signaling mechanisms to mediate nervous system
development.

For example, a mouse model with overexpression of the ShcA

Y239/240/317F form specifically in neuronal cells using the nestin-cre-lox system exhibit
microencephaly. Aside from being smaller in size, the gross architectures of the brain

from the ShcA Y239/240/317F animals were similar to that of wild-type animals, with
certain regions, such as the subventricular zone (SVZ), more severely affected.
Quantification in proliferative index and differentiation markers did not reveal any

alterations. However, there was an increase in cleaved-caspase 3 staining in the ShcA
Y239/240/317F animals, indicating that microencephaly is the result of augmented
apoptosis. Animals generated with ShcA deletion using the nestin-cre-lox strategy also

resulted in animals with microencephaly, which was initially interpreted as to suggest that

ShcA Y239/240/317F mimics ShcA deletion mutants, and thus lead to the same phenotype
[84]. However, a subsequent study focused on the role of ShcA in the SVZ revealed that the

effects of expressing ShcA Y239/240/317F and deleting ShcA are not completely the same.
It was shown that the structure in SVZ is more severely disrupted in the ShcA deletion
than the ShcA Y239/240/317F mutant animals. Deletion of ShcA resulted in enlarged

blood vessels and appearance of unidentified cell types. In contrast to an increase in
apoptosis in the ShcA Y239/240/317F mutant animal [84], ShcA deleted animals showed a
marked decrease in cell proliferation but an unaltered level of apoptosis in the SVZ [85].
Taken together, these studies indicate that in the development of the nervous system,

ShcA utilizes both Y239/240/317 phosphorylation-dependent and -independent
mechanisms, and that other domains and/or PTMs of Shc are likely involved.
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1.6 ShcA in human disease

1.6.1 Neurodegenerative disease
A role for ShcA has been implicated in Alzheimer’s disease (AD). Comparison of AD

and normal brains showed the ShcA is present at a higher level in the diseased tissue. The

C-terminal fragments of amyloid precursor protein (APP) can be tyrosine phosphorylated
[86] and recruit ShcA, which might lead to the elevated level of phospho-Erk through
enhancing the interaction between Shc and Grb2 in AD tissues [87].

1.6.2 Cancer
ShcA has been associated with cellular transformation from the first report of its

discovery, wherein ShcA overexpression led to a transformed morphology of mouse

fibroblasts and enabled colony growth in soft-agar [28]. While it has since been shown
that ShcA expression and post-translational modifications are altered in the cancer of a

number of tissues [27,88], only the role of ShcA in breast cancers has been dissected to a
great extent and hence will be discussed below.

1.6.2.1 Breast Cancer
As discussed in 1.4.1.1, tyrosine-phosphorylated p46/p52 Shc activates whereas

p66Shc inhibits Erk activation. This led to the idea that the ratio between the levels of
20

Y317 phosphorylation on ShcA and p66Shc expression can serve as prognostic markers

for breast cancer. Indeed, immunohistochemical analysis on archival primary breast

tumor specimens showed that an increase in pY-Shc and decrease in p66Shc expression

levels positively correlated with relapse of the disease, as well as with node-positive status
[89].

Furthermore, this ratio was found to be a strong predictor for disease-relapse in

patients who have undergone Tamoxifen [90].

A number of transgenic animal studies attest to the importance of ShcA in multiple

processes required for breast cancer progression. Also, the different ShcA domains and

phosphorylation sites have been found to be responsible for various oncogenic behaviors,

including tumor initiation, cell growth, cell survival, angiogenesis and metastasis. Mice
expressing activated ErbB2 in mammary epithelial cells completely failed to develop

tumors when ShcA is deleted, indicating that ShcA is critical to the development of ErbB2
breast cancer [91]. Transgenic animals expressing mutated upstream activator of ShcA
signaling also confirm its critical role in disease progression. In the Polyomavirus middle

T antigen (MT) -driven mammary tumor model, a delay in tumor onset was observed in
mice carrying the MT mutant in which the ShcA binding site is compromised. Even though

tumors eventually developed and metastasis occurred, a reversion to the wild-type
sequence on the MT gene was found in the metastatic tumors [92]. Furthermore, when the
ShcA binding site is reconstituted in an ErbB2 tyrosine mutant, tumors developed earlier
[93]. Finally, a study using a chimeric RTK composed of the extracellular domain of Met

harboring either an EGFR or TrkA binding site for the ShcA PTB domain showed that the

recruitment of ShcA via its PTB domain is required for both tumor onset and angiogenesis
[94]. Hence, the oncogenic potential of active tyrosine kinases such as RTKs requires
interaction between ShcA and the kinase.
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Using the MT-driven mammary model, Urini-Siegel et. al. investigated the

importance of phosphotyrosine signaling mediated by the CH1 domain in breast cancer.
Mice homozygous for either Y239/240F or Y313F developed tumors much later than the

WT animals, indicating that the phosphorylation of these tyrosine sites are required for

tumor initiation. There were also a lower number of metastasized lesions in the lungs.
Inspection of the mutant animal breast tissues showed retention of myoepithelial cells,
which are known to suppress tumor cell invasion [95].

Y239/240 and Y313 on ShcA is important in metastasis.

Hence, phosphorylation of
As in the case of T-cell

development (1.5.3), Y239/240 and Y313 elicited different biological effects. Y313 was

found to promote cell survival, while Y239/240 is required for angiogenesis.
Furthermore, injecting tumor cells expressing WT ShcA into the fat pads of Y313F animals
led to a significantly reduced level of tumor outgrowth, whereas Y239/240F and WT

animals had comparable levels of tumor outgrowth. This indicates a possible role for
pY313 in stromal signaling, whereas pY239/240 are not important in this context [91].

It has been demonstrated that ShcA promotes angiogenesis by increasing vascular

endothelial growth factor (VEGF) expression in a number of studies [91,94,96,97,98].

First, p52 Shc leads to an increase in the expression of α5 and β1 integrins. This in turn

leads to the Src-dependent VEGF production as well as platelet derived growth factor

(PDGF) receptor and hepatocyte growth factor (Met) receptor transactivation [98].

Second, in line with a role of Y239/240 in angiogenesis [91], p52 Shc activates Akt in a
pY239/240/317-dependent manner. Activated Akt in turn inactivates 4EBP1 triggering
the release of eIF4E and translation of VEGF [97].

ShcA also activates Akt via its SH2 domain to promote cell survival. Disabling the

phosphotyrosine binding ability in the SH2 domain leads to a decrease in phospho-Akt
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level and a significant increase in apoptosis. As it has been shown that Shc recruits
tyrosine phosphorylated 14-3-3 via its SH2 domain for the activation of PI3 kinase (the

upstream activator of Akt) [65], the association between Shc and 14-3-3 was investigated.
Indeed, it was found that there was a reduction in the association between Shc and 14-3-3,

as well as p85, suggesting that Shc activates Akt through the recruitment of the 14-3-

3/p85 complex [96].

Transgenic animals expressing the ShcA R175Q mutant, which cannot bind to

phosphotyrosine-motifs via the PTB domain, exhibited delayed tumor onset. However,

these mice eventually developed tumors that grew to a large size with enhanced

angiogenesis. In agreement with enhanced angiogenesis, profiling of tumors derived from

these mice expressing ShcA R175Q mutant reveals a gene signature that associates with a
higher microvessel density in breast cancer patients [98]. Since Y239/240 in the CH1 and

SH2 domains are associated with angiogenesis, this suggests that abolishing PTB functions
causes a bias towards CH1 and SH2 functions

These studies support the finding in mouse developmental models that the three

ShcA core domains function non-redundantly as discussed in section 1.5. Intriguingly, no

change in proliferative rate was found in most of the studies that investigated this aspect
[91,96,98]. Cell proliferation is closely linked to Erk signaling, with which ShcA is most

associated in cell culture transformation studies. Furthermore, in certain cases, Shc/Grb2
association and/or phospho-Erk level was not altered. Whether this is due to differences

in signaling when experiments were carried out in a three-dimensional (i.e. in an organ)

verses a two-dimensional environment (i.e. in monolayer cell culture) remains to be
investigated.
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1.7 Summary
The prototypical scaffold ShcA is involved in diverse cellular processes and the

disruption of Shc-mediated signaling leads to disease states. Developmental and breast
cancer mouse models have successfully assigned some of these cellular processes to
certain domains/PTMs of ShcA.

For example, in mouse breast cancer models, the

phosphotyrosine-binding ability of ShcPTB is required for tumor initiation, whereas the
SH2 domain is responsible for angiogenesis; also, phosphorylation of Y239/240, but not
Y317, is important in DN3-DN4 transition of T- cells.

However, these studies also reveal

that the molecular mechanisms for some of the Shc-dependent functions are unclear. For

example, deleting ShcA in the nervous system downregulates cell proliferation. It was

shown that a pY239/240/317-independent mechanism was involved, however, the exact
nature of this mechanism is currently unclear.
development, ShcA deletion led to lethality.

Again, in the case of cardiovascular

Mutating tyrosine 239/240/317 to

phenylalanine in mice led to grossly normal heart development and only affected Erk

signaling moderately, indicating that the lethal effect of ShcA deletion is caused by
mechanisms other than those mediated by the phosphorylation of Y239/240/317. Since it
is known that Shc recruits a large array of protein factors, it is likely that these unknown

mechanisms rely on the interaction between Shc and these protein factors. Hence, many
questions remain as to how the interactions between Shc and each of its partners
contribute towards biological outcomes at the molecular level.
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1.8 Research objectives
To investigate novel mechanisms whereby intracellular signaling networks are

regulated by scaffold proteins, we utilized Shc as a model system because it has been
shown to lie at the intersection of a number of signaling pathways. I have previously

identified the MAP kinase Erk as a potential interacting partner. In this thesis I investigate,
1) the molecular basis for the direct interaction between Shc and Erk, 2) the regulation of

Erk signaling by Shc prior to growth factor stimulation and 3) the role of Erk-mediated
phosphorylation of Shc in downstream signaling post- EGF stimulation.
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Chapter 2

Materials and Methods

2.1 Materials

2.1.1 Chemicals
All chemicals were purchased from Sigma or Fisher, unless otherwise stated.
2.1.2 Enzymes and growth factor
Enzymes
Vent DNA polymerase
Phusion DNA polymerase
T4 DNA polymerase
Restriction endonucleases
T4 DNA ligase
Recombinant EGF
Dpn1 demethylase

Supplier
NEB
NEB
NEB
NEB
NEB
R&D
NEB

Kits and other materials
Talon superflow resin
Glutathiones agarose
Q Sepharose
Sephadex G-75
Sephadex G-200
Protein A/G agarose
Complete Protease inhibitor Cocktail with EDTA
PhosphoSTOP phosphatase inhibitor cocktail
Metafectene transfection reagent
Immobilon-P PVDF membrane
QIAprep spin miniprep kit
QIAquick gel extraction kit
Enhanced chemiluminescence substrate
Silver stain kit
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Supplier
Clontech
Sigma or GE
GE
GE
GE
Santa Cruz
Roche
Roche
Biontex
Millipore
Qiagen
Qiagen
Pierce
Pierce

2.1.3 Kits and other materials

X-ray film

Denville

2.1.4 Bacterial cell culture reagents
Luria-Bertani (LB) broth
1.0% (w/v) tryptone
0.5% (W/V) yeast extract
0.5% (w/v) sodium chloride

Antibiotic working concentrations
All were 0.22μm filtered
Ampicillin: 50μg/ml (dissolved in H2O)
Kanamycin: 50μg/ml (dissolved in H2O)
Chloramphenical: 50μg/ml (dissolved in ethanol)
LB-Agar plates
1.0% (w/v) agar was added to LB broth followed by autoclaving. Antibiotics were added
to cooled agar.

E. coli. glycerol stocks
Glycerol stocks were prepared by mixing 700μl 50% autoclaved glycerol and 300μl E. coli
overnight culture. Stocks were stored at -80oC.
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2.1.5 Mammalian cell culture reagents
Reagent

Supplier

Dulbecco’s Modified Eagle’s Medium

Lonza

(DMEM)
DMEM/F12
RPMI
Foetal Bovine Serum
Horse Serum
Hydrocortisone
Cholera Toxin
EGF
Insulin
Pen/Strep/Fungizone

2.1.5 Composition of complete growth media
HEK293T,

MCF7,

MKN28,

NIH3T3,

Invitrogen
Lonza
Denville
Sigma
Sigma
Sigma
Peprotech
Sigma
Invitrogen

MDA-MB-468,

supplemented with 10% FBS and Pen/Strep/Fungizone.

MDA-MB-231,

A431:

DMEM

PC12: DMEM supplemented with 10% HS, 5% FBS and Pen/Strep/Fungizone.
MDA-MB-361: DMEM/F12 supplemented with 10% FBS and Pen/Strep/Fungizone.
MCF10A: DMEM/F12 supplemented with 5% HS, 20ng/ml EGF, 0.5mg/ml hydrocortisone,
100ng/ml cholera toxin, 10μg/ml insulin and Pen/Strep/Fungizone.
Composition of starvation media:
HEK293T,

MCF7,

MKN28,

NIH3T3,

supplemented with Pen/Strep/Fungizone.

MDA-MB-468,
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MDA-MB-231,

A431:

DMEM

PC12: DMEM supplemented with Pen/Strep/Fungizone.
MDA-MB-361: DMEM/F12 supplemented and Pen/Strep/Fungizone.
MCF10A: DMEM/F12 supplemented with 0.5mg/ml hydrocortisone, 100ng/ml cholera
toxin and Pen/Strep/Fungizone.

Antibiotics for cell line selection
Antibiotic
Blasticidin
Hygromycin
Puromycin

Cell line
HEK293T
HEK293T
MCF7

2.1.6 Antibodies
Antibody
Erk1/2
Phospho-Erk1/2
EGFR
Tubulin
LaminA/C
Hsp90
GST
Shc

Shc
Shc
Strep-tag
Phospho-Thr-Pro
Phospho-Akt (T308)
Akt
PhosphoShc
(T214)
Grb2
Phospho-Shc
(Y239/240)
Phospho-Shc (Y317)
GAPDH
HA-tag

Concentration
100μg/ml
160μg/ml
4 μg/ml

Cat. No.
4695
4377
2646
2125
4777
4874
2625
MAB0807

Supplier
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Abnova

sc-255
2434

Santa Cruz
Cell Signaling Technology

sc-967
610879
PAB-16601
9391
4056
4691
Custom

sc-23765R
sc-47724
sc-805

Santa Cruz
BD Biosciences
Abnova
Cell Signaling Technology
Cell Signaling Technology
Cell Signaling Technology
Genscript

Santa Cruz
Santa Cruz
Santa Cruz
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Use
Western Blot
Western Blot
Western Blot
Western Blot
Western Blot
Western Blot
Western Blot
Western blot/
Immunoprecipitation
Western Blot
Immunoprecipitation
Western Blot
Western Blot
Western Blot
Western Blot
Western Blot /
Immunoprecipitation
Western Blot
Western Blot
Western Blot
Western Blot
Immunoprecipitation

14-3-3 (pan)
GFP
Myc-tag
GFP-trap
PIN1
GFP-trap

8312
sc-9996
2278
gta-20
sc-15340
Gta-20

2.1.7 Plasmids
Plasmid
pcDNA6 Myc/His C

pcDNA6 Myc-His C-Erk WT

pcDNA6 Myc-His C-Erk
D20/100A
pGEX6P-Erk2 WT
pGEX6P-Erk2 D20/100A
pET28 Erk2
pcDNA 3.1
pcDNA3.1 Strep-tagged
WT
pcDNA3.1 Strep-tagged
R98Q
pcDNA3.1 Strep-tagged
T214/276/407A
pcDNA3.1 Strep-tagged
T214/276/407E
pET28b
pET28b p52Shc
pET28b ShcPTB
pET28b
T214/276/407E
pGEX2T

Shc
Shc
Shc

Shc

p52Shc

pGEX2T ShcPTB

pGEX2T ShcPTB R98Q

pGEX2T ShcPTB W24A

pGEX2T ShcPTB R175Q

Cell Signaling Technology
Santa Cruz
Cell Signaling Technology
Chromotek
Santa Cruz
Chromotek

Western Blot
Western Blot
Western Blot
Immunoprecipitation
Western Blot
Immunoprecipitation

Characteristics
Mammalian expression vector with a Myc
and His tag at C-term driven by CMV
promoter
Mammalian expression of myc-tagged Erk
WT
Mammalian expression of myc-tagged Erk
D20/100A
Bacterial expression of Erk2 WT
Bacterial expression of Erk2 D20/100A
Bacterial expression of Erk2
Mammalian expression driven by CMV
promoter
Mammalian expression of strep-tagged Shc
WT
Mammalian expression of strep-tagged Shc
R98Q
Mammalian expression of strep-tagged Shc
T3A
Mammalian expression of strep-tagged Shc
T3E
Bacterial expression vector of N-term Histagged protein with T7 promoter
Bacterial expression of p52Shc
Bacterial expression of p52Shc PTB domain
Bacterial expression of p52Shc T3E
Bacterial expression vector of GST-tagged
protein
Bacterial expression of GST-tagged ShcPTB
domain
Bacterial expression of GST-tagged ShcPTB
domain R98Q
Bacterial expression of GST-tagged ShcPTB
domain W24A
Bacterial expression of GST-tagged ShcPTB
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Source
Invitrogen
This study
This study

This study
This study
This study
Invitrogen
This study
This study
This study
This study
Novagen

This study
This study
This study
GE

George et. al.
This study
This study
This study

pGEX2T ShcSH2
GST-Pin1

GST-Pin1 C113A
pMCSG7 Pin1

GFP-N 14-3-3 zeta

pGEX4T2 14-3-3 Tau

pGEX4T1 14-3-3 Epsilon
pCI HA Nedd4

domain R175Q
Bacterial expression of GST-tagged ShcSH2 George et. al.
domain
Bacterial expression of GST-tagged Pin1
Addgene
#19027
Bacterial expression of GST-tagged Pin1 This study
C113A mutant
Bacterial expression of His-tagged Pin1
Addgene
#40773
Mammalian expression of GFP-tagged 14- This study
3-3 zeta
Bacterial expression of GST-tagged 14-3-3 Addgene
Tau
#13281
Bacterial expression of GST-tagged 14-3-3 Addgene
Epsilon
#13279
Mammalian expression of HA-tagged Addgene
Nedd4
#27002

2.1.8 Stock solutions and buffers
Comassie blue stain solution

0.2% (w/v) Coomassie brilliant blue R
40% (w/v) Methanol
10% (w/v) Acetic acid
Comassie blue destain solution
40% (w/v) Methanol
10% (w/v) Acetic acid
Lysis buffer for mammalian cells
50mM HEPES, pH7.5
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50mM NaCl
1mM EGTA
10% (w/v) Glycerol
1mM Sodium orthovanadate
10mM Sodium fluoride
0.1% NP-40
1x protease inhibitors
Ponceau S stain solution
0.1% (w/v) Ponceau S
5% (v/v) Acetic acid
Rapid screening buffer
5mM EDTA
10% (w/v) Sucrose
0.25% (w/v) SDS
100mM NaOH
60mM KCl
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0.05(w/v) Bromophenol blue
SDS-PAGE running buffer (10X)
1.9M glycine
250mM Tris-base
10% (w/v) SDS

TBE buffer (10x)
890mM Tris-base
890mM Boric acid
20mM EDTA
TBS (10x)

63.04g Tric-HCl
12.11g Tris-base
87.99g NaCl
TBS-T (1x)
1x TBS
1mM EDTA pH8.0
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0.1% Tween-20
Transfer buffer stock (10x)
30.3g Tris-base
144g Glycine
Transfer buffer (1x)
1X transfer buffer stock
20% Methanol
DNA loading dye (6x)
0.25% (w/v) Bromophenol blue
0.25% (w/v) Xylene cyanol
30% (v/v) glycerol
Laemmli loading buffer (6x)
300mM Tris-HCl pH6.8
60% (v/v) Glyerol
12% (w/v) SDS
0.6% (w/v) Bromophenol blue
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30mM DTT (add before use)
Talon A
50mM Tris-base pH8.0
100mM NaCl
Talon B
50mM Tris-base pH8.0
100mM NaCl
200mM Imidazole
Talon resin regeneration
20mM MES pH5.0
300mM NaCl
GST A
20mM HEPES pH7.5
100mM NaCl
5mM BME
GST B
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20mM HEPES pH7.5
100mM NaCl
10mM reduced glutathione
5mM BME
GST resin regeneration
100mM Sodium acetate
500mM NaCl
Anion exchange A
50mM Tris-base pH8.0
100mM NaCl
5mM BME
Anion exchange B
50mM Tris-base pH8.0
500mM NaCl
5mM BME

2.1.9 Peptides
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Name
TrkA
pT214

2.2 Molecular biology

Sequence
HIIENPQpYFSDA
NPPKLVpTPHDRMAG

Purpose
ITC studies
Antibody production

2.2.1 Restriction cloning
To amplify a relevant segment of a gene, a set of primers with Tm between 58-64oC were
designed by the following equation:

no. of T or A bases x2 + no. of C or G bases x4 for the complementary bases
Corresponding restriction sites were added to the ends of the primers, with additional
bases required for a particular enzyme.

Polymerase chain reaction (PCR)was set up as follows:
10ng DNA template
2uM of Each primer
2μl DMSO
1x Enzyme buffer
2μl DNTP
1μl Enzyme
Add sterile H2O to 50μl

37

Thermal cycles:
1x

95oC for 5min

30x

95 oC for 1min
56-62 oC for 1min (use 2 oC below the lowest Tm of the two primers)
72 oC for 30s for every 1kb

1x

72oC for 10min

∞

4 oC

PCR products were run out on agarose gels at the indicated percentage. PCR products
were then purified by gel extraction per manufacturer’s instructions.

Purified PCR

products and vectors were digested by the appropriate restriction enzymes. Digested
products were either cleaned or subjected to one more round of gel extraction. Digested
PCR products and vectors were ligated as follows:

Vector: products at 1:3 ratio (at least 10ng of vector)
1x T4 ligase buffer
1μl of T4 ligase for every 10μl of ligation reaction
Add H2O to the appropriate final volume
Ligation was carried out either overnight at room temperature or for 2 hrs at 37 oC.
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Ligation products were transformed into DH5α. DNA from single colonies was subjected
to further analysis.

2.2.2 Mutagenesis
Primers were designed using the online software Primer X. Briefly, 20-25bp on either side
of mutation were included in the primers with C/G content between 30% to 60%.
PCR was set up as follows:
50ng DNA template
2μM of each primer
1x Enzyme buffer
2μM DMSO
1μl Enzyme
2μl DNTP
Add sterile H2O to final volume of 50μl
Thermal cycles:
1x

95oC for 5min

30x

95 oC for 1min
55oC for 1min
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68 oC for 2min for every 1kb
1x

68oC for 10min

∞

4 oC

1μl of Dpn1 was incubated with the mutagenesis products to digest DNA template for
1.5hrs at 37 oC. The product was then cleaned up and transformed into DH5α. DNA from

single colonies was subjected to further analysis.
2.2.3 Transformation

Plasmids were incubated with DH5α or Rosetta 2 cells for 30min on ice. Cells were then
incubated at 42oC for 1.5 min (routine plasmids production) to 2.5 min (cloning products).
Cells were snap cooled on ice for 2min and allowed to recover in 1mL LB at 37 oC with

shaking for 1hr. Cells were then pelleted, resuspended in 100μl LB and plated on agar
plates containing appropriate antibiotics.
2.2.4 DNA extraction
5-10ml of LB was inoculated either with a single colony or glycerol stock. Cells were

pelleted and DNA extraction was performed using the Qiagen miniprep kit.
2.2.5 Generation of competent cells

Inoculate 5ml of LB with bacterial cells for an overnight culture. Add overnight culture to

fresh LB in a 1:100 dilution the next morning. Grow cells at 37oC until OD600 is 0.4-0.45.
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Cool on ice for 15 min. Then pellet cells at 5000g for 15 min at 4oC. Remove supernatant
and add 40% of the original volume of ice-cold 150mM CaCl2 (freshly made). Resuspend
cells gently and incubate on ice for 60min. Cells were then pelleted at 5000g for 15min.
Supernatant was removed and cells were resuspended in 4% of the original volume of ice-

cold 150mM CaCl2. Cells were incubated on ice for 15 min. Cells were stored in 30%
glycerol at -80 oC in small aliquots.

2.3 Cell biological methods

2.3.1 Maintenance of mammalian cell lines
Mammalian cells were maintained in their appropriate media as listed in 2.1.5 at 37oC with

5% CO2. Cells were split at 1:5 ratio when they reach 80% confluency and replenished
with fresh media every three-four days.

2.3.2 Transfection of mammalian cell lines
HEK293T Cells were seeded the day before for 80% confluency on the day of transfection.

Manufacturer’s instruction was followed for the ratio of DNA amount, cell numbers and
transfection reagent. Cells were used for assays between 1 and 4 days after transfection.
2.3.3 Lentiviral infection of mammalian cell lines
Cells were seeded the day before infection for 50% confluency on the day of infection.

5μg/ml of Polybrene and lentiviral particles were added to the culture media at the end of
the day. Cells were replenished with fresh culture media the next morning.
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2.3.4 Generation of stable cell lines
24hrs after transfection or infection, cells were split in 1:5 ratio with fresh media
. The appropriate antibiotic was added to the culture media the next day and maintained
until non-transduced cells died. Transduced cells were maintained and expanded for
analysis.

2.3.5 Preparation and recovery of frozen stocks of mammalian cells
Cells were grown to 80% confluency, trypsinized and resuspended in 3-5ml of media

(from a T75 flask), depending of cell types. Resuspended cells were then mixed at a 1:1

ratio with 20% DMSO and 80% FBS. Cells were frozen in 1.8ml aliquots. Each aliquot is
sufficient for a T75 flask of cells. Cells were first frozen in an alcohol freezing carrier at -

80oC for 1-2 days before moving into long-term liquid N2 storage. Cells were recovered by
via a quick thaw in the water bath and placed into warm culture media.
2.3.6 Fluorescence lifetime imaging microscopy (FLIM)
The EKARnuclear reporter was transfected into HEK293T cells in 12-well format with 1ug of
the plasmid DNA. 24hrs after transfection, cells were seeded onto coverslips at 2.5x105 to

achieve 50% confluency the next day. Once the cells acquired the necessary confluency,

they were starved for 18-24hrs. Starved cells were then washed with PBS and fixed in 4%
paraformaldehyde for 20 minutes at room temperature. Samples were mounted in the
presence of anti-fading agent. The FLIM measurements were performed on a Leica TCP
SP5 confocal microscope system with internal PMT FLIM detector. Samples were excited
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with a titanium-sapphire–pumped laser (Mai Tai BB, Spectral Physics) with SPC830 data

and image-acquisition card for time-correlated single photon counting. Data processing
and analysis were carried out with B&H SPC FLIM analysis software.
2.3.7 Immunoprecipitation
Cells were lysed in lysis buffer (typically 1ml of lysis buffer was used on a 10cm-dish) and
cleared by centrifugation. One milligram of lysate was used per IP experiment. IP antibody
was added to the lysate and incubated for overnight. 25 µl of Protein A/G slurry was
added to the lysate for 2 h. The immunoprecipitants were washed three times with lysis
buffer and boiled with 2× sample buffer (Bio-Rad) for 5 min to elute.
Antibody

Dilution factor/Amount

Shc (BD Bioscience, 610879)

5μg

Shc (mouse)

10μg

Phospho Shc pT214 (Custom)

7.5μl

2.4 Protein expression and purification
2.4.1 His-tagged full-length Shc proteins
pET28-Shc FL plasmids were transformed into Rosetta 2 cells. Either a single colony or

glycerol stock was used to inoculate overnight culture supplemented with antibiotics.
1mL of overnight culture was then used to inoculate 1L of LB supplemented with

antibiotics the next day. Bacterial culture was grown to OD600 0.8 at 37oC and temperature
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was reduced to 20oC. It was then induced with 0.1mM IPTG for overnight. Cells were
pelleted and stored at -20oC until required.

To purify ShcFL proteins, cell pellets were lysed in Talon buffer A supplemented with
protease inhibitors. Lysates were cleared by centrifugation at 20,000rpm for 1hr at 4oC.

Cleared lysates were then applied to Talon resin using the AKTA chromatography system.

Bound proteins were washed with 5 column volumes each of Talon buffer A and 7.5%
Talon buffer B. Proteins were eluted in 100% Talon buffer B. Eluted proteins were then

applied to the anion exchange column in anion exchange column A and subjected to a
gradient from 0% to 100% anion exchange column B over 10 column volume. ShcFL

proteins are eluted between 20-25% B. ShcFL fractions were pooled and concentrated to

5mL before being applied to size exclusion chromatography using a SD75 column (~120ml
volume) in the appropriate buffer for subsequent assays.
2.4.2 His-tagged ShcPTB proteins

Growth conditions are as described in 2.4.1.
To purify ShcPTB proteins, the same protocol is used as in 2.4.1, except the anion exchange
step is not necessary.

2.4.3 GST-tagged ShcPTB and ShcSH2 proteins
Growth conditions are as described in 2.4.1.
To purify GST-tagged ShcPTB and ShcSH2 proteins, cells were lysed and cleared as in 2.4.1.

Lysates were incubated with Glutathione resin for at least 2hrs at 4oC. Resin was then
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washed with 50mM Tris-base pH8.0, 200mM NaCl and 1% Triton-X100 5-10 times at 10x
bead volumes. Proteins immobilized on beads were stored at 50% glycerol at -20oC until

required for assay.

2.4.4 His-tagged Erk2 protein
Growth conditions and purification procedures are as described in 2.4.2.
2.4.5 GST-tagged Erk2
Growth conditions and purification procedures are as described in 2.4.3.
2.4.6 GST-tagged Pin1 proteins
Growth conditions and purification procedures are as described in 2.4.3.
2.4.7 His-tagged Pin1
Growth conditions and purification procedures are as described in 2.4.2.
2.4.8 GFP-14-3-3 zeta
HEK293T cells were transfected with 20 µg of GFP-N-14-3-3 zeta plasmids on a 10cm-dish.
Cells were harvested and lysed in 1ml of lysis buffer 48hrs after transfection.

Cleared

lysates was incubated with 50ul GFP-trap beads overnight. Beads were washed with 1ml
lysis buffer 5-10 times.
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2.4.9 GST-tagged 14-3-3 Tau and Epsilon proteins
Growth conditions and purification procedures are as described in 2.4.3.
2.4.10 HA-tagged Nedd4
HEK293T cells were transfected with 20ul of pCI-HA-Nedd4 plasmids in a 10cm dish. Cells
were harvested and lysed in lysis buffer 48hrs after transfection.

Cleared lysates was

incubated with HA-tag antibody overnight and subsequently incubated with protein A/G
for 2 hrs. Beads were washed with 1ml lysis buffer 5-10 times.
2.5 Biochemical methods

2.5.1 Western blotting
Samples separated by 10% or 4-15% SDS-PAGE and transferred to a PVDF membrane
(0.45um) at 250mV for 2hrs or 25mV for 16hrs. Membranes were then blocked with 5%

milk or 5% BSA for 30minutes for the detection of total and phospho-protein, respectively.

Primary antibody was added at appropriate dilution for overnight at 4oC. Excess antibody

was washed with TBST three times before the addition of the secondary antibody in TBST.

This was followed by three TBST washes. Signals were developed by the addition of ECL
and membranes were exposed to X-ray films [99].
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2.5.2 5,5'-Dithio-bis-(2-nitrobenzoic acid) (DTNB) assay
DTNB reacts with a free sulfhydryl group to yield TNB, which absorbs at 412nm with an
extinction coefficient of 14,150M-1cm-1.

10μM purified ShcFL proteins in 0.1M sodium phosphate and 1mM EDTA was incubated
with 80μg /mL DTNB for 15minutes at room temperature. Absorbance was measured at
412nm.

2.5.3 In vitro Erk2 phosphorylation of Shc
50 μl of 10μM purified ShcFL proteins in PBS were incubated with 1μl of active Erk2 (NEB,
P6080) in the presence of 5mM buffered ATP and 10mM MgCl2 overnight.
2.5.4 Two-dimensional gel electrophoresis
Samples were eluted in 200ul of rehydration buffer containing 7 M urea, 2 M thiourea, 1%
ASB-14, 40mM Tris, 0.001% Bromophenol Blue (Biorad).

(Biorad) were then incubated with the eluents overnight.

11cm pH5-8 ReadyStrips

The Protean i12 system

(Biorad) was used to separate samples according to their isoelectric points, using the
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‘gradient’ program for the appropriate strip size and pH range. Samples were then
separated by molecular weights using 10% SDS-PAGE gels.
2.5.5 Limited proteolysis
Chymotrypsin preferentially cleaves peptide amide bonds where the carboxyl side of the
amide bond is either tyrosine, tryptophan or phenylalanine, thus causing proteolysis in a
limited and targeted fashion. 100ng of ShcFL proteins were incubated with 0.5ng of

chymotrypsin in PBS at 37oC for each time point. Digestion process was terminated by the
addition of 2X loading sample buffer and boiling for 5min.
2.6 Biophysical methods

2.6.1 Isothermal titration calorimetry (ITC)
ITC measures the change in heat (enthalpy) in a bimolecular interaction which leads to the

determination of the full range of thermodynamic parameters of the bimolecular
interaction. When two molecular species bind non-covalently, a number of bonds are

formed or broken between the two molecular species, as well as between the molecular
species and the solvent.

These can be hydrogen bonds, van der Waals forces and

hydrophobic interactions. The rearrangement of interactions thus produces a change in

heat as one species is titrated into another, which is measured as the power per second

required to maintain the same temperature between the reference and sample cells
(Figure 1).
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Figure 1. Schematic of the basic components of an ITC instrument. One of the protein

binding partners is loaded into the sample cell and the ligand is titrated into the sample
cell gradually with constant stirring to ensure the ligand and protein are mixed rapidly.
The temperature in the sample cell is constantly monitored by a sensor and compared to

the temperature in the reference cell. When there is a change in temperature in the
sample cell as the ligand is titrated into the sample cell, the heater then alters the amount
of heat that is applied to the sample cell to bring it to the same temperature as the
reference cell.

The change in heat of each titration of the ligand is then used to determine the enthalpy,

binding constant and stoichiometry of the interaction between the two binding partners
using the following equations:

Q=nATΔH(V/2)·{X-[X2-(4BT/nAT)]1/2}
and
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X={1+BT/nAT)+ (1/nKBAT) }
Where Q is the heat content of a particular titration (which is experimentally determined
by the power required to maintain the same temperature between the reference and

sample cells). A is the component in the sample cell and B is the ligand titrated into the
sample cell. n is the stoichiometry of the interaction between A and B. T is the total

amount of a particular component. H is the enthalpy of the interaction. V is the volume of
the reaction. KB is the binding constant for the interaction between A and B. It is
converted into KD as follows:

KB=1/KD
The molar calorimetric enthalpy and the equilibrium binding constant is determined
directly by ITC. We then obtain the full range of thermodynamic parameters using the
following equation:

-RTInKB=ΔG=ΔH-TΔS
Where R is gas constant and T is the absolute temperature. S is the entropic term of the
interaction.

Experiments were performed using either a VP or iTC200 instrument (GE).

All

experiments involve Erk2 binding interactions were carried out in 20 mM HEPES, pH 7.4,
50 mM NaCl, 3 mM EDTA and 5 mM βME. ShcPTB proteins binding to TrkA peptide were

carried out in 50 mM Tris, pH8.0, 200 mM NaCl. All other experiments were carried out in
PBS. ORIGIN7 software was used for data analysis using the single-site model.
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2.6.2 Microscale thermophoresis (MST)
MST describes the flow of molecules induced by a temperature gradient. An infrared
source heats up the sample at a specific spot, creating a thermal gradient of up to 5K

between that specific point and its environment. The bound and unbound species move
differently through the temperature gradient due to differences in their hydration shell

(which is affected by size/conformation). To monitor the movement of the bimolecular

complex in this study, the protein is fluorescently labeled, which is excited by the infraredlaser.

The amount of fluorescence in the heated spot at a given time is determined by

images taken of the heated spot (Figure 2A). Several steps in the MST process of a
bimolecular complex can be monitored and used to determine the binding constant for the
bimolecular interaction (Figure 2B).
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Figure 2. Basic principle for MST measurements. A) Protein samples are loaded into

glass capillaries. An infrared source heats up the sample at a particular spot. The laser is

turned on and off at specific times controlled by the user. The fluorescence at the heated
spot is determined from images taken at that spot. B) Several steps in the MST process
can be used to determine dissociation constant. Prior to the laser being switched on, the

labeled molecules emit a certain level of fluorescence (initial state). At the early stage

after the laser is switched on, molecules in the heated spot migrate into (or out of) the
environment in the process of thermophoresis. Eventually, equilibrium of this movement
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of molecules is reached (steady state). Finally, the laser is turned off, the molecules
redistribute (backdiffusion).

In a bimolecular interaction in an MST experiment:
A+B⇌AB
Where A is the fluorescently labeled protein and B is the unlabeled binding partner.
To determine the dissociation constant for in this thesis, the following equation was used:
(Fnorm[B]-Fnorm[A])/(Fnorm[AB]- Fnorm[A])={1/(2[A])}{[A]+[B]+Kd-{([A]+[B]+Kd)2-4[A][B]}1/2

Where Fnorm is the normalized fluorescence. [ ] denotes concentration of the species in the
brackets. Kd is the dissociation constant.

Protein was labeled using the NanotTemper labeling kit. Briefly, ShcPTB was diluted to

20μM in labeling buffer to the final volume of 100μl. 60μM of dye NT-647 was added to

the diluted protein and incubated for 2-4hrs at room temperature. ShcPTB was then

separated from the free dye using a G25-sephadex column in PBS. Labeling efficiency was

calculated by determining the concentrations of the dye (molar extinction coefficient:
250,000M-1cm-1) and ShcPTB. To test binding between ShcPTB and ligands, a 1:2 dilution
series of each ligand was prepared with a final volume of 10μl. 10μl of 25nM of labeled
ShcPTB was added to the ligands and loaded into capillaries.
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2.6.3 Circular dichroism (CD)
CD measures the differential absorption of circularly polarized light by chiral molecules.
Circularly polarized light is either left-hand circular (LHC) or right-hand circular (RHC).

Chirality of a molecule is generated when the molecule is placed in an asymmetric
environment, as in the case of protein secondary structures. Secondary structures, such as
α-helices and β-strands give rise to certain CD signatures [100,101], as shown below in
Figure 3.

Figure 3.

CD signatures of secondary structures.

Secondary structures exhibit

differential absorbance for LHC and RHC light at certain wavelengths. The overall CD
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signal of a protein with multiple types of secondary structure is the sum of the CD signal
from all secondary structures. θ is ellipticity.

Differential absorbance for LHC and RHC light is calculated as follows:
ΔA=ALHC-ARHC
Where A is absorbance of a particular wavelength.
Absorbance is related to θ:
θ=32.98 ΔA
All CD spectra were recorded at room temperature a Jasco J-810 spectropolarimeter in

PBS. Data was collected at 0.2nm intervals in triplicates. Data was plotted as molar
ellipticity verses wavelength.

2.6.4 Differential scanning fluorimetry (DSF)
DSF monitors the unfolding of a protein by detecting the increase in fluorescence of a dye

that interacts with hydrophobic patches of the protein (Figure 4).
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Figure 4. Principle of DSF for monitoring protein stability. Native protein is incubated
with a dye that binds to hydrophobic patches on proteins and fluoresces.

As the

temperature increases, the native protein melts to become increasing denatured to expose
hydrophobic patches. Tm is the temperature at which 50% of the protein is denatured.

5μM ShcFL proteins are incubated with 1X SYPRO Orange dye to a final volume of 10μl at

4oC for 20 minutes. Melting assay is performed on Roche LightCycler 480 instrument.

Dye was excited at 483nm and emission was monitored at 568nm. Fluorescence is
monitored between 20oC and 95oC.

Fluorescence signals from the fully folded and

unfolded states was then estimated manually and plotted as 0% (fully folded) to 100%
(fully unfolded).
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Chapter 3

Interaction with Shc inhibits Erk activity in the absence of extracellular stimuli

3.1 Introduction
The family of mitogen-activated protein kinases (MAPKs) plays important roles in

diverse cellular processes.

The best-characterized MAPK is the extracelluar signal-

regulated kinase (Erk). It is the terminal member of a kinase cascade that can be activated
by receptor tyrosine kinases (RTKs), which transduce and convert extracellular signals

into intracellular events, in turn allowing cells to appropriately respond to the
environment. Many steps of this process have been shown to be deregulated in human

disease such as cancer. For example, gain-of-function mutations can be found in Ras in

90% of pancreatic cancer; 70% of melanoma patients possess B-Raf mutations. Therefore,
members of the Erk cascade are targeted in cancer treatment [102].

Upon binding to their cognate ligands, RTKs are activated and autophosphorylates

on their tyrosine residues. The phosphorylated receptors then recruit various adaptor
proteins, resulting in the recruitment and activation of the GTPase Ras. One of the
effectors of Ras is the serine kinase Raf, the first kinase in the Erk cascade. Raf in turn

activates the dual-specificity kinase Mek, which then phosphorylates and activates Erk.
Erk has two well-characterized functionally and structurally similar isoforms: Erk1 and
Erk2 (85% sequence homology; henceforth communally referred to as Erk). Erk is a

serine and threonine kinase that functions primarily by phosphorylating a wide range of
substrates [60,103,104]. Activated Erk phosphorylates two proteins critical to cell-cycle

entry, p90RSK and Elk [105,106]. p90RSK phosphorylates SRF, which, together with Elk
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bind to the serum-response-element (SRE) [107]. SRE is the promoter for immediateearly gene such as c-fos, whose activation leads to cell-cycle entry and therefore cell
proliferation [108,109].

Erk is tightly controlled by a number of mechanisms. As mentioned above, Erk

requires phosphorylation by Mek to become activated upon stimulation of RTKs

[110,111]. Erk is dephosphorylated and hence inactivated by a class of dual-specificity
phosphatases, named MKPs [112]. Scaffolding proteins such as KSR are also responsible
for maintaining the efficiency of the Erk cascade by binding to multiple members of the
pathway [113]. It has also been demonstrated that Erk can be anchored in the cytoplasm
by proteins such as PEA15 [114,115,116].

In this Chapter, I describe the mechanism whereby direct interaction of Shc with

Erk inhibits Erk activity prior to extracellular factor stimulation. This interaction blocks
the phosphorylation of Erk and restricts its nuclear translocation. The binding sites

identified on both the PTB domain of Shc and the N-terminal lobe of Erk, have not been
previously shown to take part in protein recognition. On epidermal growth factor

stimulation, recruitment of Shc to phosphorylated RTKs through the PTB domain causes a
conformational change in this domain which releases Erk, allowing it to take part in

downstream signaling. Thus, Shc is revealed as a key negative regulator of MAP kinase
signaling in non-stimulated cells and switches to a positive regulator on binding to

activated RTKs through both release of Erk and recruitment of downstream effector

proteins.
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3.2 Results

3.2.1 Shc forms a complex with Erk prior to extracellular stimulation
Through a proteomics-based study work in the Ladbury lab have previously shown

that Shc has many binding partners. Many of these protein binding partners have not been
fully characterized [25].

This prompted us to search for other potential interacting

partners for Shc. We found that several scaffold proteins with similar functions to Shc in
early signaling complexes have been reported to be Erk substrates (see Section 4.1).
Therefore, we investigated whether Shc and Erk are directly involved in RTK signaling.

To explore if Shc and Erk interact in mammalian cells, we immuno-precipitated Shc

in three different cell lines and immunoblotted for Erk. In serum-starved NIH3T3, MKN28
and PC12 cells we observed the endogenous complex between Shc and Erk (Figure 1A-C).

In all three cell lines the stimulation of endogenous epidermal growth factor receptor
(EGFR) by EGF reduces the Shc association with Erk (Figure 1A-C). Since Shc is known to
associate with EGFR, it appears that the activated, phosphorylated receptor disrupts the

binding of Erk. In a reciprocal experiment, GST-tagged Erk immobilized on glutathione
agarose beads was incubated with HEK293T lysates and immunoblotted for endogenous
Shc. The formation of the Shc-Erk complex was again apparent and this dissociated on
stimulation of endogenous EGFR (Figure 1D).
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Figure 1. Shc forms a complex with Erk in the absence of extracellular stimulation.
(A)-(C) After overnight serum starvation, cells were stimulated with 20ng/ml EGF
(NIH3T3 and MKN28 cells), or 100ng/ml (++) and 50ng/ml (+) EGF (PC12 cells). 1 mg of

whole cell lysate was incubated with anti-Shc antibody overnight prior to the addition of

protein A agarose beads. Immunoprecipitants were washed with lysis buffer and

separated by SDS-PAGE, followed by western blot analysis for the presence of Erk. (D)

Purified and immobilized GST-Erk was incubated with 1mg of HEK293T cell lysate
overnight. The presence of bound Shc was confirmed by western blotting.
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3.2.2 Shc binds directly to Erk
To assess the strength of the interaction between Shc and Erk, we quantified the

direct binding of full-length Shc and Erk in vitro using isothermal titration calorimetry

(ITC). Both Shc and Erk were expressed recombinantly in E. coli. Shc was titrated into Erk.

The equilibrium dissociation constant (KD) was found to be 0.9µM (Figure 2) for the
formation of a 1:1 complex between Shc and Erk.

Figure 2. Shc binds directly to Erk. ITC measurement of the Shc and Erk interaction.

Thirteen 3µl injections of Erk (60µM) were titrated into Shc (6µM) at 15ºC . Top panel:
baseline-corrected power versus time plot for the titration (black) and the heat of dilution

of Erk titrated into buffer (red; offset by −0.04 μcal/s). Bottom panel: the integrated heats
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and the molar ratio of Erk binding to Shc. The data were corrected for the heats of dilution
of Erk and fit to a one-site binding model.

3.2.3 Role of Shc in Erk phosphorylation in non-stimulated conditions
Having established that Shc and Erk form a complex under non-stimulated

conditions, we investigated the effect of Shc on Erk phosphorylation.

We depleted

endogenous Shc in MCF7 cells by shRNA. To our surprise, the pErk level was up-regulated

when Shc protein level is depleted (Figure 3A). Since activated Erk translocates into the
nucleus [117], we performed nuclear extraction assays to assess the accumulation of Erk
in the nucleus of the Shc knock-down cells. Analysis of MCF7 Shc knock-down and control

cells fractionated into cytoplasmic and nuclear fraction, demonstrated an increased level
of Erk was present in the nuclear fraction when endogenous Shc was diminished in MCF7

cells (Figure 3B). This suggests that Shc functions to inhibit Erk activity in the absence of
growth factor stimulation.

Figure 3. Shc downregulates Erk activation. (A) MCF7 cells were infected with either

scrambled shRNA (control) or Shc shRNA and starved overnight. 50µg of total cell lysates

were analyzed by western blotting for endogenous pErk. Shc-depleted cells exhibit a high

level of pErk compared to those with the control shRNA. (B) Nuclear extraction was
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performed on Shc-depleted MCF7 cells. Cells were obtained from 10cm-dishes for each

sample. All of the nucleus extracts and 50µg of cytoplasmic fractions were analyzed by
western blotting. More total Erk was found in the nucleus when the endogenous Shc level
was reduced.

3.2.4 Shc-Erk interaction occurs through unique binding sites on both proteins.
To determine whether the inhibitory effect of Shc on Erk is mediated by the direct

interaction of the two proteins, we next identified the molecular basis for the Shc-Erk

complex. The CH1 domain of Shc has been shown to form complexes only upon Shc

phosphorylation by active protein tyrosine kinases [118,119], therefore the binding site

for Erk on Shc was assumed to involve either the N-terminal PTB domain or the C-terminal
SH2 domain. ShcPTB and ShcSH2 fused with GST were recombinantly expressed in E. coli.

and purified. Purified GST-ShcPTB and GST-ShcSH2 proteins were incubated with either
HEK293T or PC12 lysates.

Figures 4A and 4B indicate that the ShcPTB, and not the

ShcSH2, forms the binding site for Erk.
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Figure 4. Identification of ShcPTB-Erk interaction. Purified GST-ShcSH2 or GST-ShcPTB

were incubated with 500ug of (A) HEK293T or (B) PC12 total cell lysates. Cells were

starved overnight. The ability of endogenous Erk to bind to the individual domains of Shc
was analyzed by western blotting

To confirm that ShcPTB is responsible for directly interacting with Erk, the

interaction of ShcPTB and Erk was measured by ITC. Erk was titrated into ShcPTB (KD =
9.5µM; Figure 5). The affinity of the ShcPTB interaction with Erk with a KD of 9.5µM is

about an order of magnitude weaker than the interaction with the full length Shc protein
with a of KD of 0.9µM. Since the interaction between full-length Shc with Erk fitted well

with a single-site model, the stronger affinity between the full length proteins is unlikely to

be due to additional unidentified sites on the CH1 or SH2 domains. We have previously

shown that the functions of ShcSH2 are affected by the CH1 domain [118], indicating that
inter-domain interaction exists in the Shc molecule. Extending that rationale to this result,

it is likely that the weaker affinity between Erk and ShcPTB compared with full length Shc
is due to the CH1 and SH2 domains stabilizing the binding of the PTB domain with Erk

through inter-domain interaction.
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Figure 5. ITC measurement of the ShcPTB and Erk interaction. ShcPTB (203µM) was

titrated into Erk (20µM) at 15ºC. Top panel: baseline-corrected power versus time plot for

the titration (black) and the heat of dilution of buffer titrated into Erk (red; offset

by −0.04 μcal/s). Bottom panel: the integrated heats and the molar ratio of ShcPTB binding

to Erk. The data were corrected for the heats of dilution of Erk and fit to a one-site binding

model.

Small angle X-ray scattering (SAXS) was employed to provide a model for the

molecular juxtaposition of ShcPTB and Erk in the complex [120]. The SAXS-derived model

for the complex between ShcPTB (purple) and Erk (green) revealed that the α2-β3 loop of

Shc PTB binds to a groove in the N-terminal lobe of the Erk kinase domain (Figure 6A and
B).
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Figure 6. Determination of the binding interface between ShcPTB and Erk. (A)
Atomic model of the Erk-ShcPTB complex (Erk, green; ShcPTB, magenta). (B) Close-up

view of a structural model of the interaction between the ShcPTB peptide (cyan) and the
Erk N-terminal lobe (green). Additionally highlighted are Shc R98, Erk D20 and D100.

The interaction of Erk on Shc is mediated through a previously unidentified binding

site which is independent of both the canonical phosphotyrosine and phospholipid binding

sites on ShcPTB [35,44]. To validate the binding site for Erk on Shc as seen in the SAXS

analysis, a peptide based on the Shc sequence (Shc3R: RRRKPCSRPLS residues 97-107 of

Shc) was synthesized and tested for binding to full length Erk. ITC data show that the

Shc3R peptide binds to Erk with a KD of 5.7µM (Figure 7). The binding affinities of Erk for
ShcPTB and Shc3R peptide are in the same order of magnitude (9.5 µM verses 5.7µM),

suggesting that the residues required for interacting with Erk on Shc are mostly contained
within the Shc3R peptide.
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Figure 7. ITC measurement of the binding between Erk and ShcPTB 3R peptide.
Thirty-nine 7µl injections of Shc3R peptide (250µM) were titrated into Erk (10µM) at

15ºC. Top panel: baseline-corrected power versus time plot for the titration (black) and
the heat of dilution of buffer titrated into Erk (22 injections shown in red; offset

by −0.04 μcal/s). Bottom panel: the integrated heats and the molar ratio of Shc3R peptide
binding to Erk. The data were corrected for the heats of dilution of Erk and fit to a one-site
binding model.

Mutants in the putative binding site for Erk on ShcPTB were generated to confirm

the interaction suggested by the SAXS model. The model predicts that R98 in the α2-β3

loop of ShcPTB plays a major role in the recognition of Erk (Figure 6B). To test whether
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this residue was necessary to mediate this binding, we mutated the arginine to a glutamine
(R98Q;

R98QShcPTB).

We also made two other control mutant Shc variants (W24A and

R175Q). A key residue in a potential consensus Erk substrate binding site, W24, was

mutated to Ala (W24A; W24AShcPTB), whilst R175, a critical residue in the phosphotyrosine

binding pocket recognized by RTKs, was mutated to glutamine (R175Q;

R175QShcPTB).

These mutants were recombinantly expressed as GST-fusion proteins and purified. The
data reveal that R98 is a direct binding residue to Erk, as shown in Figure 8A (upper
panel), in which the

R98QShcPTB

fails to pull-down endogenous Erk from HEK293T cell

lysates. This data also confirms that the location of the binding site on ShcPTB as that
including the sequence incorporated in Shc3R and depicted in Figure 3B. The two other

point-mutants

W24AShcPTB

and

R175QShcPTB

retain the ability to interact with Erk.

Furthermore, we tested the ability of the

R98QShcPTB

in binding to a tyrosyl

phosphopeptide based on the TrkA receptor, a well-characterized ShcPTB binding partner

[35]. ITC titrations show that there is no difference in the binding affinities of TrkA for
WTShcPTB

and

R98QShcPTB

(Figure 8B and C, suggesting that the R98 residue is involved

specifically in the interaction of Shc with Erk and not tyrosine-phosphorylated binding

partners. Taken together, the location of the binding site for Erk on Shc does not include
sites for other reported Shc interactions.
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Figure 8. ShcPTB binds to Erk via a noncanonical site. (A) Top panel: GST-fusion of
ShcPTB containing 3 different mutations (R98Q, W24A or R175Q) were immobilized on
agarose beads and incubated with unstimulated HEK293T lysates. Erk from HEK293T

lysates was pulled down by WTShcPTB, W24AShcPTB and R175QShcPTB. Only R98QShc disrupts

the formation of the Shc-Erk complex.
WTShcPTB

(B) ITC measurement of the binding between

and TrkA peptide. Twenty 15µl injections of TrkA peptide (100µM) were

titrated into WTShcPTB (10µM) at 15ºC. The data were corrected for the heats of dilution

of Erk and fit to a one-site binding model with a KD of 140nM. (C) ITC measurement of the
binding between

R98QShcPTB

and TrkA peptide.
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Twenty-five 12µl injections of TrkA

peptide (100µM) were titrated into R98QShcPTB (10µM) at 15ºC. The data were corrected
for the heats of dilution of Erk and fit to a one-site binding model with a KD of 250nM.

The modeled binding site for Shc on Erk also represents a novel mode of interaction

not previously identified as a site of ligand binding on the kinase. To confirm the location

of binding site two aspartic acids which were identified as being in the Erk binding site in
the SAXS model (Figure 6B), D20 and D100, were mutated to alanines (D20A/D100A;
D20A/D100AErk).

This mutant form of Erk was unable to pull down Shc from HEK293T cell

lysate (Figure 9).

Figure 9. Erk binds to Shc via a novel site. GST-fusion with WTErk or D20/100AErk were

immobilized on agarose beads and incubated with unstimulated NIH3T3 cell lysates. The
immunoblot shows that

D20/100AErk

diminishes the ability of Erk to bind to endogenous

Shc. *Indicates non-specific protein bands.

3.2.5 Physiological role of Shc-Erk binding.
Having demonstrated the existence of the Shc-Erk complex in non-stimulated cells

and identified the binding sites on the respective proteins, we investigated the
physiological effects of the interaction. To test whether the Shc-Erk complex affects Erk
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phosphorylation we established stable HEK293T cell lines over-expressing WTShc and the
mutant

R98QShc.

Under non-stimulated conditions, the overexpression of

WTShc

R98QShc

overexpression does not influence Erk phosphorylation level (Figure 10A).

reduces

the level of pErk compared with cells transfected only with the control plasmids, whereas
The above observations are supported by similar experiments in HEK293T cells

stably expressing the

D20A/D100AErk

mutant in which the Shc-Erk interaction is abrogated.

Again pErk levels increase in the mutant compared to wild type Erk-expressing cells
(Figure 10B). These data demonstrate the inhibitory role that Shc has on Erk
phosphorylation in the absence of extracellular RTK stimulation mediated by direct
interaction between the two proteins.

Figure 10. Shc binding has an inhibitory effect on Erk phosphorylation. (A) HEK293T

cells stably over-expressing either strep-tagged WTShc, R98QShc or strep-tag alone (control)

were starved overnight. The phosphorylation level of endogenous Erk was analyzed by

western blotting. Erk is more phosphorylated in cells over-expressing R98QShc than WTShc

under non-stimulatory conditions. (B) HEK293T cells stably over-expressing Myc-tagged
WTErk
WTErk

or

D20/100AErk

were starved overnight.

under non-stimulatory conditions.
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D20/100AErk

is more phosphorylated than

Next, we used a specific Erk reporter system in a fluorescence lifetime imaging

microscopy (FLIM)-based assay to test the levels of nuclear pErk [121]. The reporter

EKARnuclear contains an N-terminal GFP, followed by a WW phospho-binding domain, a

substrate peptide, an Erk-docking domain and RFP at its C-terminus (Figure 11A).

Activated Erk binds to this reporter through the Erk docking-domain and then

phosphorylates the substrate peptide, which subsequently serves as a docking site for the

WW phospho-binding domain. This binding event causes a conformational change in the
reporter such that the GFP is in close proximity to the RFP and allows for fluorescence
resonance energy transfer between the two fluorophores. This results in a shortening of

the lifetime of GFP emission. We co-transfected HEK293T cells with the nuclear-localized

form of EKAR (EKARnuclear) and either WTErk or D20/100AErk. We then measured the lifetime

of the GFP fused to EKARnuclear. We observe a clear shortening of the EKARnuclear GFP
lifetime in the presence of D20/100A Erk compared to in the presence of WTErk (right panels).
This demonstrates the presence of a greater concentration of phospho-Erk in the nucleus

of the D20/100AErk-overexpressing cells compared to WTErk-overexpressing cells in the nonstimulated state (Figure 11B).
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Figure 11. Erk activity in the nucleus. (A) Schematic of the structure of the Erk activity

reporter structure. The reporter EKARnuclear contains an N-terminal GFP, followed by a

WW phospho-binding domain, a substrate peptide, an Erk-docking domain and RFP at its

C-terminus. (B) HEK293T cells were transiently co-transfected with EKARnuclear and either
vector, Myc-tagged

WTErk

or Myc-tagged

D20/100AErk.

starved for 18-24hrs. Overexpression of the

24hrs after transfection, cells were

D20/100AErk

mutant results in a left-shift of

EKARnuclear fluorescence lifetime (histogram), indicating higher Erk activity in the nucleus

compared with cells overexpressing
WTErk

and D20/100AErk.

WTErk.

Western blot shows equal overexpression of
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3.2.6 Binding of tyrosyl phosphopeptide to ShcPTB promotes dissociation of Erk.
The above characterization of the interaction and the functional consequences of

the Shc-Erk complex relate to conditions in the absence of extracellular stimulation. Since
the endogenous Shc-Erk complex is present at a reduced level upon growth factor

stimulation (Figure 1A-E), we investigated the mechanism by which Erk escapes the
inhibitory regulation of Shc. The dissociation of the Shc-Erk complex does not appear to be
associated with tyrosyl phosphorylation of Shc by activated RTKs, since ITC data shows
that Erk can still bind to phosphorylated Shc (KD=0.8µM. Figure 12).

Figure 12. ITC measurement of tyrosine phosphorylated Shc with Erk. Twenty 15ul

injections of Erk (96µM) were titrated into tyrosine-phosphorylated full-length Shc

(10µM) at 15oC. Integrated heats of the titration were corrected for heats of dilution and
fitted to a one-site binding model. The KD for the Erk-Shc interaction was 0.84µM.
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Comparison of NMR spectroscopic structural data on the apo- and TrkA-bound

forms of ShcPTB revealed that the apo-form is partially disordered [36]. Regions

associated with the binding of TrkA peptide are particularly dynamic. The binding of TrkA

peptide results in reorganization of the binding site through local folding events which

appear to trigger a conformational switch between free and complex states [35,36]. Large

changes in chemical shifts were observed in the region in direct contact with TrkA peptide

(the β2-α2 loop region), as well as in part of α2. Q76, R79 and E80 point toward the α2-β3

loop that contains the Erk-binding Shc3R motif (Figure 13). Residues from the α2-β3 loop

region also experience significant change in chemical shifts, especially S103 which is facing

Q76, R79 and E80 of the α2- β3 loop. Based on these data we hypothesize that the
dissociation of the Shc-Erk complex results from an allosteric mechanism, whereby tyrosyl

phosphopeptide binding induces structural changes onto the β2-α2 loop which are
propagated via helix α2 to the Erk-binding motif.

Figure 13. Proposed allosteric changes in ShcPTB responsible for Erk dissociation.
Selected NMR chemical shift changes highlighted onto ShcPTB structure (PDB: 1SHC).
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TrkA peptide is shown as stick model (magenta).

The phosphate group of the

phosphotyrosine is indicated by an arrow. Grey: chemical shift changes, cluster1, β2-α2
loop region residues 61-70; orange: cluster 2, α2 (residues 72-87). Residues 75-80 within

α2 display the largest chemical shift changes of all ShcPTB residues and are shown as stick

models; red: cluster3, residues from the α2- β3 loop which also experience significant
chemical shift changes, especially S103.

To confirm this allosteric model we tested if the presence of a known tyrosyl

phosphopeptide ligand could provoke the abrogation of the Shc-Erk complex. ShcPTB was
titrated into Erk in the presence of TrkA peptide in an ITC experiment. No binding
between Shc and Erk was observed. This suggests that TrkA abrogates the Shc-Erk

complex formation (Figure 14A).

In addition we demonstrated that the Shc-Erk interaction was inhibited by tyrosyl

phosphorylated ligand binding in a pull-down experiment (Figure 14B). HEK293T cells

over-expressing strep-tagged WT Shc were starved overnight and the exogenous Shc was
precipitated by strep-tactin agarose beads and washed under non-stringent conditions.

TrkA peptide was incubated with the precipitants. In the presence of the peptide the
interaction between Erk and Shc was abrogated as shown by the absence of Erk from the
eluted fractions. These data support a mechanism for tyrosyl phosphorylated ligandstimulated dissociation of Shc and Erk.
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Figure 14. Binding of tyrosine-phosphorylated proteins/peptides to the ShcPTB
domain inhibits Shc-Erk interaction (A) ITC measurement of ShcPTB and Erk in the
presence of TrkA peptide. 200µM of ShcPTB was pre-incubate with 275µM of TrkA

peptide. Twenty 10ul injection of ShcPTB/TrkA complex were titrated into 20µM of Erk at

15oC.

No interaction between Erk and Shc was detected.

expressing strep-tagged

WTShc

(B) HEK293T cells over-

were starved overnight. Total cell lysates were incubated

with agarose beads coated with strep-Tactin for 2 hours. Beads were washed and
incubated with buffer or 900µM pTrkA peptide for an additional 1hr. Beads were then

washed and precipitants were analyzed by western blotting for the presence of Erk. In the
presence of the tyrosyl phosphopeptides no interaction of Shc and Erk was detected.

77

3.2.7 Screening for small molecules to stabilize the Shc-Erk complex
A recent breast cancer study using a mouse model shows that abrogating the

tyrosyl phosphopeptide binding ability of the ShcPTB domain delays tumor development

[98]. In light of our present finding, we reasoned that a molecule that can block Shc
binding to activated RTKs without introducing a conformational change in the Erk-binding
site could be beneficial to the treatment of ErbB2-driven breast cancer.

An in silico screen (Dr. C. Montanari, personal communication) revealed several

potential hits for molecules that could inhibit the binding of Shc with activated RTKs. One

such molecule was the nonsteroidal anti-inflammatory drug indomethacin. It has been

reported that indomethacin possesses anti-tumor properties, however its mode of action
has not been identified. To establish whether this compound can inhibit Shc and activated
RTKs, we tested for indomethacin binding to ShcPTB. However, we were unable to
observe interaction between the two molecules as monitored by microscale
thermophoresis (MST).
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Figure 15. MST measurement of binding between ShcPTB to Indomethacin. 95nM of

fluorescently-labeled ShcPTB was incubated with the ligands in a 1:2 dilution series at

25oC. The movement of ShcPTB was monitored by fluorescence measured at 647nm. Left
panels: normalized thermophoresis traces. Right panels: Data fitted to one site model.
Thermophoresis with temperature jump measurements were made at 90% LED power

and 20% IR power. (A) ShcPTB binding to TrkA peptide with KD=1.2±0.219 µM. Top

concentration of TrkA dilution series was 15 µM. (B) ShcPTB binding to TrkA peptide in
the presence of 1mM Indomethacin; KD=452±176nM. Top concentration of TrkA dilution
79

series was 15 µM. (C) ShcPTB does not bind to indomethacin. Top concentration of
indomethacin dilution was 5M. (D) Chemical structure of Indomethacin.

In an attempt to identify potential inhibitors for the Shc PTB-RTK interaction an

initial screen of a library of tyrosyl phosphomimetics using differential scanning
fluorescence (DSF) was adopted. This resulted in one potential binder for the Shc PTB

domain (Dr. G. Poncet-montange, personal communication; Figure 16A). To determine a

dissociation constant (KD) for this interaction, we performed a MST experiment. As shown

in Figure 16B, the KD is ~100µM, which is two orders of magnitude weaker than the

binding between ShcPTB and the TrkA peptide.

A short peptide was designed based on the known PTB-phospho-peptide structure

(NPQpYFS). This peptide lacks the residues that might be responsible for triggering the
conformational change in the PTB domain that leads to Erk dissociation while retaining

the residues that are important in phosphotyrosyl binding. The KD for this interaction is
again ~100µM (Figure 16C). Although the binding affinities of Shc PTB domain for these
two peptides are considerably lower than its affinity for its intracellular target RTKs

(Figure 16E), these peptides serve as good templates for further chemical modifications to
yield more suitable compounds.

80

Figure 16. MST measurement of binding between ShcPTB to short peptides. 25nM of

fluorescently-labeled ShcPTB was incubated with peptides in a 1:2 dilution series at 25oC.

The movement of ShcPTB was monitored by fluorescence measured at 647nm. Left
panels: normalized thermophoresis traces. Right panels: Data fitted to one site model.
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Temperature jump measurements were made at 70% LED power and 20% IR power. (A)
ShcPTB binds to TrkA peptide with KD=535±74nM. Top concentration of TrkA peptide
dilution series was 80µM. (B) ShcPTB binds to tyrosyl mimetic no. 18 with KD=155±41µM.

Top concentration of no. 18 dilution series was 1mM. (C) ShcPTB binds to short TrkA

peptide with KD=83±17µM. Top concentration of short TrkA peptide dilution series was
200µM. (D) Chemical structure of tyrosyl mimetic no. 18.

3.3 Discussion
Many elegant mechanisms for the roles of kinases [122], phosphatases [123] and

scaffolding proteins [115,124] have been discovered in the regulation of kinase activity
post-extracellular stimulation. However, significant basal kinase activity occurs in cells

even in the absence of extracellular stimulation [125,126,127], for which requires control
mechanisms to prevent aberrant cellular response. Here we report a novel mechanism in
which Shc prevents aberrant signal transduction by Erk in cells prior to extracellular

stimulation. We show that prior to growth factor stimulation, Shc and Erk interact directly

in a non-canonical manner through the N-terminal lobe on Erk and the α2-β3 loop on the
ShcPTB domain. These regions are independent of the previously reported binding-motifs
on both proteins.

By forming a complex with Shc, Erk phosphorylation level is

downregulated and nuclear translocation is restricted. This is in contrast to the wellestablished role of Shc as an activator of the Erk cascade post-stimulation of growth factor
in which through the recruitment of Grb-Sos complex.

This report adds to the growing list of other discoveries we have made in the

regulation of background signaling. We previously identified a role for the adaptor protein
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Grb2 in inhibiting FGFR2 signaling by forming a heterotetrameric complex with the
receptor [127].

Furthermore, Timsah et. al. described a mechanism whereby Grb2

competes with Plc-gamma in the absence of extracellular stimulation to inhibit cell

motility [125].

Since Shc contributes towards various aspects of ErbB2-driven breast cancer, we

investigated if there is any evidence that the Shc-Erk interaction may play some part in
disease progression. Based on our finding, we reasoned that if the inhibition of Erk by Shc

was important in cancer, we might find 1) mutations on either of the protein at the binding
interface and 2) downregulation of Shc expression through either gene disruption or

micro-RNA action. However, having examined various public databases available, we did

not observe any of the above. However, in line with our observation in mammalian cell
lines, work in Caenorhabditis elegans shows that disrupting the Shc1 gene leads to
Erk/MPK-1 activation [120]. Alignment of the C. elegans and human Shc1 gene reveals

that while the Erk-binding site is conserved, the two Grb2 binding sites are not [79].

Therefore, it is possible that we do not observe any downregulation of Shc expression in

cancer because it is more advantageous for cancerous cells to upregulate the Shc-Grb2 axis

than to disengage Erk from Shc. In fact, it has been shown that Shc sensitizes cells towards
growth factor stimulation. This is particularly true in diseases that are driven by active
tyrosine kinases, in which ShcPTB is likely to be recruited to phosphotyrosine motifs such

that Shc-Erk would be dissociated ‘permanently’. Thus, the Shc-Erk direct interaction is

likely to be important in vivo, as highlighted by the finding in C. elegans, under certain
circumstances.

Both Shc and Erk possess numerous known intracellular binding partners. The

distinct domains of Shc provide docking sites for a diverse array of signaling molecules
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[25,26]. Erk also has several consensus sites for docking substrates and scaffold proteins

[128,129]. However, the ShcPTB-Erk binding site is independent of these reported sites.
The closest reported site to the one we observe for the ShcPTB-Erk interaction, involves
the scaffold protein Ste5 binding to a site on the N-terminal lobe of Fus3 MAPK from the

yeast mating cascade [132]. However the corresponding site on the N-terminal lobe of Erk

is obstructed by Erk’s own N-terminus and hence preventing ligand binding. Furthermore,

the kinase suppressor of Ras (KSR) protein which serves a similar function as Ste5 in
mammals but evolved separately, does not contain a similar sequence as Shc (i.e. rich in
positive charges) in the cysteine-rich 4 domain, where it interacts with Erk [133].

While the Erk-binding site is specific to ShcPTB, it is conserved among the Shc

family members (Figure 17a). This suggests that this mode of Erk regulation is also
mediated by ShcB, ShcC and ShcD.

Since ShcB/C/D are expressed in tissue-specific

manners, it would be interesting to see if and how the Shc-Erk interaction is involved in
these tissues. Furthermore, while ShcA expression is not downregulated in cancers,
ShcB/C/D genes are deleted in certain cancers. What the implications are for the Shc-Erk

complex in these diseases require further investigation.

Alignment of members of the

MAPK family shows that the Shc-binding site is conserved, suggesting that other MAPKs

may also directly interact with Shc. This would have important implication in signaling
outcome as the various members of the MAPK family mediate different phenotypic
responses (Figure 17b) [130,131].

The role of Shc as an adaptor protein in stimulated cells forming a docking platform

for enzymes in signaling pathways is well established. The involvement of Shc in signal
transduction in response to growth factor stimulation is contrasted by its function in the

absence of cellular stimulation. One notable interaction in this context is the binding of Shc
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to protein phosphatase 2A (PP2A) under basal conditions [41]. Similar to Erk, PP2A is
released on stimulation by EGF or insulin-like growth factor 1 (IGF-1). Furthermore, the

Shc-PP2 complex is believed to negatively regulate growth factor signaling by preventing
phosphorylation of Shc and the subsequent recruitment of Grb2-Sos complex. While PP2A
also associates with ShcPTB, dissociation of the two proteins require the presence of Y317.
Thus, it seems unlikely that PP2A binds to ShcPTB in the same manner as Erk.

Erk has been shown to be anchored in the cytosol by proteins other than Shc. For

example, the phosphoprotein protein enriched in astrocytes 15 (Pea-15) has been
demonstrated to bind to Erk regardless of its phosphorylation state and depletion of Pea-

15 show leads to increased levels of Erk in the nucleus [115]. The similar expression to

FGF (Sef) protein also regulates Erk cellular localization. This is achieved by Sef binding to
activated forms of Mek and preventing the dissociation of Erk from the Mek-Erk complex

[134]. Again knock down of Sef results in nuclear accumulation of Erk in stimulated cells.

However, although Pea-15 and Sef exert control of spatial distribution of Erk (the latter in

stimulated cells only), neither are involved in induction of MAPK signaling as in the case of
Shc.

Finally, we attempted to identify small molecules that can inhibit Shc-RTK binding

in order to sequester Erk activity. Such compounds could be useful in diseases driven by

Erk activity with an overexpression of Shc. Taking short-listed ‘hits’ from in silico and DSF

screens, we identified two chemicals that can bind to ShcPTB. However, the affinities of
these two chemicals for ShcPTB are too weak to compete with RTK-binding. Therefore,
further chemical modifications are required.
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Figure 17. Sequence
alignment of (A) PTB
domain of Shc family

members and (B) MAPK
family members.

Sequence alignment was
performed by
ClustalW2.

86

Chapter 4

Shc phosphorylation mediates crosstalk between MAPK and AKT pathways through
protein recruitment
4.1 Introduction
Posttranslational modifications are important in signal transduction due to their

inducibility and reversibility which enables the signaling cascades to be regulated in a

context dependent and transient manner as discussed in Chapter 1. Specialized protein
domains recognize most PTMs, conferring specificity when relaying intracellular signals

[10,135,136,137]. Of the numerous PTMs identified to date, phosphorylation remains to
be the best characterized modification in RTK signaling [138]. At the physiological pH, the
attachment of a phosphate group adds a double-negative charge to the modified amino
acid. This relatively dramatic change in the polypeptide enables it to regulate protein

function by altering protein conformation and protein-protein interactions [17].

Upon ligand binding to RTKs, intracellular signal transduction is initiated by the

autophosphorylation of the receptors on tyrosine residues. These phosphorylated

tyrosines, together with their flanking amino acids, then recruit downstream tyrosine-

binding proteins which lead to the activation of downstream signaling cascades. One of
the downstream effectors of RTK signaling is the proline-directed serine/threonine kinase
Erk. While activated Erk phosphorylates various downstream effectors as discussed in

Section 3.1, it also phosphorylates scaffolding proteins involved in early signaling as
feedback mechanisms (Figure 1). For example, the scaffolds Grb2-associated binding
protein (Gab1) [139,140,141,142], fibroblast growth factor substrate 2 alpha (Frs2α)
[143,144] and insulin receptor substrate 1 (IRS1) [104,145], which are tyrosine
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phosphorylated by the receptors upon growth factor stimulation as part of early signal

transduction, are also Erk substrates. It has been shown that serine/threonine and
tyrosine phosphorylation are inversely correlated events, suggesting a negative feedback
mechanism whereby phosphorylation on serine/threonine residues of Gab1 and Frs2α

leads to a reduced level of tyrosine phosphorylation. Since tyrosine phosphorylation is the
event that is required to initiate downstream signaling, reduction in signaling through this

phosphorylation results in negative feedback mechanism for pathway control.

[142,143]. Interestingly, a positive feedback role for serine/threonine phosphorylation on
scaffold proteins has also been shown. For example, Erk phosphorylation of Gab leads to

an enhancement of p85 subunit recruitment to Gab and increases PI3K and Erk signaling,
indicating a positive feedback mechanism. While the molecular details for how these

phosphorylation events mediate feedback in signaling requires further characterization, it
was noted that one of the phosphothreonine sites on Gab are in close proximity to the
phosphotyrosine site responsible for p85 recruitment and increases Gab and p85 binding.

Since p85 has not been shown to bind to phosphoserine/threonine motifs, this suggests
that these phosphothreonine events on Gab induces local conformational changes that

enable Gab to recruit p85 more efficiently [146]. Hence, RTK signaling is initiated by
tyrosine kinases but terminated or amplified by serine/threonine kinases, such as Erk.

This raises the possibility that by juxtaposing tyrosine and serine/threonine residues on
the same scaffold protein, scaffold proteins can fine-tune RTK signal transduction through
altering protein-protein interactions.
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Figure 1.

Erk phosphorylates scaffold proteins to fine-tune RTK signaling.

Activated receptor tyrosine phosphorylates scaffold proteins to activate downstream
effectors, such as the Erk cascade. Activated Erk then phosphorylates scaffold proteins on

their threonine/serine residues. The threonine/serine-phosphorylated scaffold proteins
subsequently down- or up-regulate the activity of the Erk cascade as feedback
mechanisms, possibly through protein recruitment.

Several novel phosphorylation and a neddylation sites have been identified

recently.

The timing of phosphorylation on S29, T214 and S335 suggests that these

events are mediated by downstream effectors, such as AKT for S29. An increase in cell

proliferation when Shc -/- MEFs were reconstituted with the triple phospho-deficient

mutant (S29/T214/S335AShc) indicates a negative feedback loop is mediated by these sites

[26]. Lys3 on Shc has been identified as a site which is neddylated by NEDD8 in T-cell

signaling [147].

Having established that Shc and Erk interact directly prior to growth factor

stimulation in Chapter 3, we describe the identification of three Erk-mediated

phosphothreonine sites on Shc both in vitro and in breast cancer cell lines post-EGF

stimulation. We show that phosphorylation on these residues leads to elevated Erk and
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Akt phosphorylation post-EGF stimulation. To investigate how these effects are mediated

we examined whether phosphorylation induces changes in Shc conformation and protein
recruitment.

We identified a number of proteins whose association with Shc is

phosphothreonine-dependent.

4.2 Results

4.2.1 Shc is an Erk substrate
Erk mediates numerous biological functions as a threonine/serine kinase [103,104].

Moreover, other scaffolding proteins have been identified as Erk substrates [140,143,145].

Having discovered a direct interaction between Shc and Erk, we investigated whether Shc
is also a substrate for Erk.

This would have important implications in feedback

mechanisms whereby Erk regulates the functions of Shc in downstream signaling. Three

threonine residues on Shc are contained within the Erk consensus substrate sequence
(S/T-P). To test if Shc is an Erk substrate, we incubated purified Shc with active Erk2 in

the presence of ATP and MgCl2. The phosphorylation state of the putative Erk substrate

sites on Shc was then analyzed by immunoblotting using an antibody specific for
phosphorylated threonine followed by a proline (Figure 2A).
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Figure 2. Phosphorylation of Shc on Erk substrate motifs (TP) (A) 10μM of 50μl

purified Shc protein was incubated with 1μl of active Erk2 in the presence or absence of
ATP and MgCl2 overnight. Phosphorylation of T-P motifs on Shc was analyzed by western
blotting using an antibody specific to pTP motifs.

Since the anti-Thr-Pro antibody can be detecting any one of the three phosphorylation

sites on Shc, we wanted to confirm whether all three sites on Shc are accessible for Erk

phosphorylation. Therefore, Erk-phosphorylated Shc was analyzed by mass spectrometry

and all three T-P motifs were found to be phosphorylated (Figure 2B-D). This confirms the

recent observation of T214 as an Erk substrate site [26], whereas phosphorylation of
threonines 276 and 407 on p52Shc has not been previously reported. T214 and T276 are
found in the CH1 domain, whilst T407 is in the SH2 domain (Figure 3).
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Figure 2. Mass Spectrometry analysis of phosphorylation status of Shc TP motifs.
50μl of purified Shc at 100μM and incubated with 10μl of active Erk2 in the presence of
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MgCl2 and ATP for 16h at 20 oC. The mass spectrum for (B) T214 (C) T276 and (D) T417.
Mass spectrometry measurements and analysis were performed by the MDACC core.

Figure 3. Location of the threonine residues on Shc phosphorylated by Erk. Three
threonine residues on Shc are phosphorylated by Erk: T214 and T276 are in the CH1
domain; T407 is in the SH2 domain.

4.2.2 Shc threonine phosphorylation upregulates Erk and Akt phosphorylation
To investigate the importance of threonine phosphorylation in Shc function in the

cellular environment, we mutated all three threonine residues either to alanines (TAShc

phospho-deficient mutant) or glutamic acids (TEShc phospho-mimic mutant) and stably
overexpressed these constructs in HEK293T cells. We first assayed Erk phosphorylation
in response to EGF stimulation, to test the hypothesis that Erk and Shc function in a
feedback loop post-growth factor stimulation, as has been reported for other scaffold
proteins including Gab and Frs2. We found that overexpressing

TEShc

in HEK293T cells

leads to higher Erk phosphorylation upon either a 2 min or a longer 15 min EGF
stimulation when compared with

WTShc

and

TAShc

overexpressing cells (Figure 3, top

panels). This indicates that the phosphorylation of these three threonine sites on Shc
amplifies the level of Erk phosphorylation post-EGF stimulation.

Next, we examined the level of Akt phosphorylation because Shc is also involved in

PI3K signaling (see Section 1.4.2). We observed an increase in Akt phosphorylation from 2
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minutes up until 30 minutes post-EGF stimulation in cells overexpressing TEShc compared

with cells overexpressing

WTShc

and

TAShc

(Figure 4, middle panels). This suggests that

post-EGF stimulation, threonine-phosphorylated Shc amplifies the phosphorylation level

of Akt. It also suggests that a cross-talk mechanism exists between the Erk and Akt
signaling whereby Erk-mediated phosphorylation of Shc upregulates Akt activity. This is

an unexpected result as expressing the T214A phospho-deficient Shc mutant led to a
moderate increase in cell numbers when compared with wild-type Shc in Zheng et. al. [26],

which would be indicative of a downregulation of downstream signaling when Shc is
threonine phosphorylated. This difference in our data could be due to a number of factors.

First, among the three sites in the present study, Zheng et al. only investigated the role of
T214, whereas here all three sites were simultaneously mutated. Hence, the differences in

the effects of Shc threonine phosphorylation could be due to a cooperative effect of
phosphorylation on all three threonine sites on Shc. Second, HEK293T cells were used in

this study, whereas Zheng et. al. used MCF10A cells. Different cell lines are likely to
respond to Shc threonine phosphorylation in distinct manner through a number of

mechanisms. For example, the interacting partner of threonine phosphorylated Shc that is
responsible for the upregulation in downstream signaling may not be overexpressed in the
MCF10A cells (see below) Third, since Shc is a scaffold protein, the amount of Shc

overexpressed would also affect signaling outcome due to a titration effect of protein
binding partners [24] resulting in a different outcome in our study from that of Zheng et.
al.
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Another observation is that overexpressing

WTShc

downregulated Akt and Erk

phosphorylation (compare HEK293T control and WTShc cells (Figure 4). This could be due

to the mechanism described in Chapter 3, or that multi-protein complexes are not formed
because of the high concentration of Shc titrates proteins into separate complexes.

Figure 4. Shc threonine phospho-mimic mutant leads to elevated pAkt and pErk
levels. HEK293T cells stably overexpressing either empty vector, strep-tagged
TAShc

or

TEShc

WTShc,

were starved overnight and then stimulated with 20ng/ml EGF for the

indicated time periods. 25μg of total cell lysates were analyzed by western blotting for the
phosphorylation states of Akt T308 (upper panels) and Erk (middle panels).

Equal

expression of the Shc constructs were confirmed by blotting for strep-tag (bottom panel).
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4.2.3 Shc threonine phosphorylation level in non-transformed and transformed cell
lines
Both Erk and Akt signaling play important roles in tumorigenesis [102,148]. We

hypothesize that Shc is threonine phosphorylated endogenously in cancer cells because
Erk and Akt are more phosphorylated in the presence of the Shc phospho-mimetic mutant
(TEShc) compared with

WTShc

and

TAShc

in HEK293T cells. To test this hypothesis, we

generated a specific antibody against the pT214 motif (Figure 5).

Figure 5. Specificity test for anti-pT214 antibody. Purified recombinant Shc was

phosphorylated by active Erk2 as in Figure 1. A western blot signal is only present when
Shc was phosphorylated by Erk2. This confirms that the anti-pT214 antibody is specific
for phosphorylated Shc.

We first screened for the presence of phosphorylation on T214 in a number of

transformed/cancer cell lines, with a particular interest in breast cancer cell lines due to
the critical role of Shc in this disease as discussed in Chapter 1 [149].

The non-

transformed mammary epithelial cell line MCF10A was used for comparison. Cells were
stimulated with EGF for between 2 to 30 minutes to investigate the temporal pattern of

Shc threonine phosphorylation. Cells were also pre-incubated with the Mek inhibitor
U0126 to abolish Erk activity, in order to confirm that the phosphorylation event is
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mediated by Erk. Since the antibody is not sensitive enough to detect the endogenous

level of pT214 (data not shown), we first immunoprecipitated total Shc and then probed
for pT214. To our surprise, even though all cell lines exhibited Erk activity upon EGF
stimulation, only the triple negative cell lines MDA-MB-468 and MDA-MB-231 exhibited a

significant level of phosphorylation on T214 (Figure 6). Two of the known binding
partners for Shc in EGF signaling, EGF receptor and Grb2, were probed for to confirm that
the immunoprecipitation experiments were successful.

It is interesting to note that even

though Shc does not pull-down a significant amount of EGF receptor in some cell lines, it is
still tyrosine phosphorylated and hence was able to recruit Grb2. This could be because

Shc can be phosphorylated by cytosolic kinases such as Src, which is also activated by EGFstimulation [48,63,150].

It has been reported that serine/threonine phosphorylation

affects tyrosine phosphorylation in scaffold proteins, so we examined the phosphorylation
levels on the three known Shc tyrosine sites, 239, 240 and 317.

If Shc threonine

phosphorylation affects its tyrosine phosphorylation level, we should observe a difference
in Shc tyrosine phosphorylation when the cells are treated with the Mek inhibitor.
However, we observed variable differences in phosphotyrosine levels when cells were
treated with the Mek inhibitor U0126, independent of pT214 level. For example, we

observed phosphorylation on T214 in both MDA-MB-468 and MDA-MB-231 cells. When
Shc threonine phosphorylation is indirectly abolished by the inhibition of Erk, a decrease

in the level of pY239/240 was detected in MDA-MB-468 cells and not in MDA-MB-231

cells. The reverse is true for pY317 level in these two cell lines where pY317 level is

reduced in MDA-MB-231 upon treatment with U0126, while pY317 level is unaffected in

MDA-MB-468 cells. Also, in other cell lines such as MCF10A and MCF7, while there is no

significant phosphorylation on T214, the level of pY317 is affected when cells were treated
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with the Mek inhibitor suggesting that pY317 level in these two cell lines are not affected
by the phosphorylation of T214 on Shc.

Figure 6. Phosphorylation of T214 in endogenous Shc in mammalian cell lines. Cell
lines (A)MDA-MB-468 (B)MDA-MB-231 were starved overnight and then stimulated with

20ng/ml EGF for the indicated time periods. The Mek inhibitor U0126 was applied at
10μM for 45 minutes prior to EGF stimulation in ‘5+U’ samples.
immunoprecipitated from 1mg of lysates.

Shc was

Immunoprecipitants (IP) were probed for

pT214 and pY239/240 levels of Shc, the presence of EGFR and Grb2. Whole cell lysates
(w.c.l.) of the same samples were also analyzed for pErk level and pY317 of Shc.
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Figure 6. Phosphorylation of T214 in endogenous Shc in mammalian cell lines. Cell
lines (C)MCF10A (D)MDA-MB-361 were starved overnight and then stimulated with

20ng/ml EGF for the indicated time periods. The Mek inhibitor U0126 was applied at
10μM for 45 minutes prior to EGF stimulation in ‘5+U’ samples. Shc was

immunoprecipitated from 1mg of lysates. Immunoprecipitants (IP) were probed for

pT214 and pY239/240 levels of Shc, the presence of EGFR and Grb2. Whole cell lysates
(w.c.l.) of the same samples were also analyzed for pErk level and pY317 of Shc.
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Figure 6. Phosphorylation of T214 in endogenous Shc in mammalian cell lines. Cell

lines (E)MCF7 (F) A431 (G)HEK293T were starved overnight and then stimulated with
20ng/ml EGF for the indicated time periods. The Mek inhibitor U0126 was applied at
10μM for 45 minutes prior to EGF stimulation in ‘5+U’ samples. Shc was

immunoprecipitated from 1mg of lysates. Immunoprecipitants (IP) were probed for
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pT214 and pY239/240 levels of Shc, the presence of EGFR and Grb2. Whole cell lysates
(w.c.l.) of the same samples were also analyzed for pErk level and pY317 of Shc.

In addition to analysis of pAkt and pErk, we also observed that the level of pY239/240

or pY317 does not result in a reduction in Grb2 recruitment. This is probably because the
pY239/240 or pY317 level is not completely abolished by Erk inhibition. If so, it would

suggest that a certain degree of variance in signal transduction can be tolerated by the
system. Therefore, we cannot conclude whether threonine phosphorylation is sufficient to

impact tyrosine phosphosphorylation as has been shown in other scaffolding proteins.

Another observation is that in certain cell lines, Shc-EGFR interaction is increased when
the Mek inhibitor is applied. Although it occurs in cell lines with, or without Shc T214

phosphorylation, we tested the binding of the TrkA peptide and Shc phosphorylation
mutants to confirm that modifications on T276 and T407 do not alter phosphotyrosine
binding of ShcPTB, the domain responsible for EGFR binding. ITC experiments show that,

as expected, there is no difference in the phosphotyrosine binding ability of ShcPTB within
the context of full length WTShc or TEShc (Figure 7). Hence, the increased binding between
Shc and EGFR upon Erk inhibition is not due to a direct effect of Shc threonine

phosphorylation on Shc-EGFR interaction. EGFR has been reported to be phosphorylated
on T669 by Erk [151] and that phosphorylated T669 mediates internalization of EGFR

[152]. It is therefore possible that abrogating Erk activity by the use of Mek inhibitor in
turn inhibits EGFR T669 phosphorylation and thus receptor internalization. This might
then lead to the retention of EGFR on plasma membrane and Shc-EGFR association.
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Figure 7. ITC measurement of the

WTShcFL

and

TEShcFL.

Twenty 10µl injections of

TrkA peptide (100µM) were titrated into ShcFL (10µM) at 13ºC. Top panel: baselinecorrected power versus time plot for the titration. Bottom panel: the integrated heats and

the molar ratio of TrkA binding to ShcFL. The data were corrected for the heats of dilution
of TrkA and fit to a one-site binding model. (A)

WTShcFL

(B)

TEShcFL.

Titrations were

fitted into a one-site model. KD for WTShc and TEShc are 53nM±435nM and 38nM±427nM,
respectively.

To confirm that Shc is threonine phosphorylated in MDA-MB-468 cells, we

immunoprecipitated Shc using the pT214 antibody and then probed for Shc (Figure 8).
MCF10A cells were used as comparison.

In agreement with the previous

immunoprecipitation experiments, Shc is phosphorylated on T214 only in MDA-MB-468

and MDA-MB-231 cells and not significantly in MCF10A, nor MCF7 cells. Furthermore, the
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phosphorylation of T214 is sustained throughout the time-points tested which

corresponds to the sustained activation of Erk1/2. This supports the finding that when
Shc is overexpressed in Rat-1 cells, Shc pT214 and pErk levels temporally coincide [26].

Figure 8. Phosphorylation of T214 in endogenous Shc in mammalian cell lines. Cells
were starved overnight and then stimulated with 20ng/ml EGF for the indicated time
periods. The Mek inhibitor U0126 was applied at 10μM for 45 minutes prior to EGF

stimulation in ‘5+U’ samples. Anti-pT214 antibody was used to immunoprecipitate Shc
from 1mg of lysates. Immunoprecipitants (IP) were probed total Shc. (A) MDA-MB-468
(B) MDA-MB-231 (C) MCF10A (D) MCF7
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4.2.4 Shc threonine phosphorylation does not induce significant conformational
change
We previously reported a gating mechanism driven by tyrosine phosphorylation on

Shc, whereby the SH2 domain is only available for ligand-binding when the CH1 domain is
phosphorylated on its tyrosine residues [118].

It has also been proposed that

phosphorylation on Y317 introduces rigidity to the protein and limits the dynamic

motions of the PTB and SH2 domains in molecular dynamics simulations studies
[153,154]. While these studies differ in their conclusions on whether phosphorylation

leads to an activating or inhibiting conformation in Shc, they agree on the existence of
regulation mechanisms imposed by inter-domain interactions. We therefore explored the
possibility that threonine phosphorylation induces a conformational change in Shc that
might contribute towards the upregulation of Erk and Akt signaling.

Circular dichroism (CD) measures the differential absorption of circularly polarized

light by chiral molecules. Chirality can be generated when molecules are placed in an
asymmetric environment, as in the case of protein secondary structures.

Secondary

structures, such as α-helices and β-strands, as well as disordered segments give rise to
certain CD signatures [100,101]. The structural model of the full length Shc protein
suggests that T214 and T276 reside on helices (PDB 1WCP) [154]. We therefore employed

CD to investigate the effect of threonine phosphorylation on the secondary structures of
Shc. We compared the CD signals from the full length unphosphorylated, threoninephosphorylated and

TEShc.

As expected, the CD signal of the full length Shc protein

contains a mixture of α-helical, β-strand and disorder signals (Table 1). However, we

failed to observe any significant changes in the secondary structures using this technique
as shown by the overlapping signals from the various Shc proteins (Figure 9).
104

Figure 9. CD spectral analysis of ShcFL proteins. The average of three scans at 0.5nm
intervals for each sample is plotted. Experiments were carried out at room temperature in
PBS. Blue: 5μM threonine phosphorylated Shc; Red: 5μM unphosphorylated Shc; Purple:
6μM unphosphorylated

WTShc;

signal and plotted on Excel.

Green: 6μM

TEShc.

Data was subtracted from the buffer

Table 1. Composition of Shc proteins secondary structures derived from CD spectra.
Analysis of the CD signals from ShcFL proteins was analyzed by the CDSSTR software

[155]. ShcFL proteins are composed of α-helices, β-strand, turns and disordered regions.
Both WTShc and TEShc have similar compositions.
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Shc contains nine cysteine residues with seven in the ShcPTB and one in each of the

CH1 and SH2 domains. To test if there is a change in the overall conformation of Shc such
that the accessibility of cysteine residues to solvent is altered, we incubated either WTShc

or TEShc with 5,5'-Dithio-bis-(2-nitrobenzoic acid) (Ellman’s reagent; DTNB) [156]. DTNB

is reduced by free sulfhydryl groups, such as the SH-group from cysteine, and the reduced
product TNB absorbs at 412nm. Both the wild-type and mutant proteins reacted with

DTNB to the same extent (Table 2). Since two of the phosphothreonine residues are in
ShcCH1, it is possible the conformational changes were not detected because most of the

cysteine residues are located in the PTB domain. We generated a cysteine-null mutant of
Shc and a series of single cysteine constructs. We individually mutated Ser225 and Ser344

into cysteine residues, as well as mutated in Cys316. However, all of the constructs were
expressed in inclusion bodies. Attempts at refolding the proteins were unsuccessful (data

not shown). This is probably because Shc consists of three domains and each requires
different refolding dynamic [157].

Table 2. DTNB assay of ShcFL proteins. 5μM of

WTShc

and

TEShc

80μg /mL of DTNB reagent. Absorbance was measured at 412nm.

were incubated with

Next, we investigated if the thermostability of Shc is affected by threonine

phosphorylation, which could also serve as an indication of conformational changes in
protein. To monitor protein stability, we turned to the technique DSF [158]. Either WTShc
106

or TEShc was heated up in the presence of Sypro Orange, a dye that fluoresces when bound
to hydrophobic surfaces which are exposed as the protein is melted. Again, no difference

in the stability of the WTShc and TEShc proteins was detected as reflected by the lack of Tm

shift between the melt-profile of the two proteins (Figure 10).

Figure 10. DSF analysis of the thermostability of ShcFL proteins. 5μM of WTShcFL and
TEShcFL

in PBS were incubated with 1x Sypro orange dye and heated from room

temperature to 95oC. Unfolding of proteins was monitored by increase in fluorescence and
is plotted as proportion unfolded. Red: 5μM WTShcFL; Blue: 5μM TEShcFL

Finally, we compared the pattern of chymotrypsin digestion of the Shc proteins as

conformational changes may affect its accessibility to protease digestion [159].
Chymotrypsin is predicted to cleave the CH1 domain at regular intervals.

WTShc

and TEShc

were incubated with the protease for various time periods and the digestion patterns were
analyzed by SDS-PAGE. We failed to detect any major differences in the digestion pattern
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of the two proteins (Figure 11).

Figure 11. Limited proteolysis analysis of ShcFL proteins. 100ng of

WTShc

or

TEShc

was incubated with 1ng of chymotrypsin at 37oC for various periods of time as indicated.
Samples were analyzed by SDS-PAGE, followed by silver staining.

4.2.5 Protein recruitment dependent on threonine phosphorylation of Shc
We tested the hypothesis that Erk-mediated phosphorylation regulates protein

recruitment on Shc by creating phosphothreonine-motifs. A large array of proteins bind to

phosphorylated threonine or serine residues, such as the 14-3-3 family and WW-domain

containing proteins [135,160].

We took two different approaches to examine if Shc

threonine phosphorylation affects protein recruitment.

Using the HEK293T Shc-

overexpressing cell lines we performed a two-dimensional gel electrophoresis analysis on

the proteins that bind to Shc. Cells were serum-starved overnight and then stimulated
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with EGF for 2 minutes. The 2-minute time point was chosen because the difference in

phospho-Erk level was most significant in the 293T Shc overexpressing cell lines at this
time point (Figure 4). Strep-tagged Shc and its associated proteins were pulled-down

using strep-tactin beads. These proteins were separated by their isoelectric points and
then by their molecular weights. The protein spots were then visualized by silver-stain.
TEShc

mutant exhibits increased protein recruitment compared with

mutant (Figure 12, right panel).
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WTShc

and

TAShc

Figure 12. 2-dimensional electrophoresis gel analysis of Shc protein recruitment.
HEK293T cells overexpressing

WTShc, TAShc

or

TEShc

were (A) starved overnight or (B)

stimulated with 20ng/ml EGF for 2 minutes after starvation period. Cells were lysed with

lysis buffer and strep-tagged Shc was precipitated on strep-Tactin beads. Precipitants

were separated by their isoelectric points and then by molecular weight. Protein spots
were visualized by silver stain.
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Figure 12. 2-dimensional electrophoresis gel analysis of Shc protein recruitment. .

(C) Identification of proteins which preferentially interact with the threonine mimetic
mutant ShcTE using mass spectrometry. Mass spectrometry experiments and analysis
were performed by the MDACC core.

We identified the proteins that are specifically recruited to

TEShc

and not

TAShc

as

indicated in figure 12. A number of chaperones are preferentially recruited suggesting an
unfolding of Shc protein upon threonine phosphorylation. Chaperonin 60 (CH60) is a

mitochondria chaperone protein which is consistent with the observation that p46 Shc
migrates into the mitochondria [161].

Both vimentin and heterogeneous nuclear

ribonucleoprotein F (hnRNPF) have been identified in a screen for Grb2 binding partners

(Zamal Ahmed, personal communication), which raises the possibility that Shc and Grb2
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interact with these two proteins as a complex.

Glyceraldehyde 3-phosphate

dehydrogenase (GAPDH) is an enzyme that plays important roles in metabolism, a process

that is critically linked to cancer development [162,163]. Given our observation that Shc is
threonine phosphorylated in two metastatic breast cancer cell lines (MDA-MB-468 and

MDA-MB-231; Figures 5 and 7) and that a direct role of p52 Shc in metabolism has not
been described, we performed a pull-down experiment to confirm the interaction between
Shc and GAPDH. As shown in figure 13, strep-tagged WTShc interact with GAPDH upon EGF
stimulation whereas

TEShc

interacts with GAPDH constitutively. Moreover,

TAShc

was

unable to pull-down GAPDH regardless of EGF stimulation status. Hence, the interaction
between GAPDH and Shc requires Shc threonine phosphorylation.

Figure 13. Threonine phosphorylated Shc associates with GAPDH. HEK293T cells
overexpressing

WTShc, TAShc

or

TEShc

were starved overnight and then stimulated with

20ng/ml EGF for 2 minutes. Cells were lysed with lysis buffer and strep-tagged Shc was
precipitated on strep-Tactin beads. The precipitants were immunoblotted for GAPDH.

In addition to the 2D analysis of Shc protein recruitment, we performed a literature

search for proteins whose binding to Shc might be affected by threonine phosphorylation.
112

We selected three isoforms of the scaffold 14-3-3 [164], the ubiquitin-protein ligase Nedd4
[165]and Pin1 [26,54,166]. As noted above, 14-3-3 proteins are known to binding to

phosphorylated threonine and serine residues, while both Nedd4 and Pin1 contain WW
domains that recognize either proline-rich or pThr/pSer motifs. These proteins were

overexpressed, isolated and immobilized on agarose beads through their fusion tags, and
used as bait for pull-down experiments. Since Shc is threonine phosphorylated upon EGF

stimulation within 5 minutes in the MDA-MB-468 cell line, it was used as prey. MDA-MB468 cells were starved overnight and then stimulated with EGF for 5 minutes. Erk activity

was inhibited by the use of the Mek inhibitor U0126 to abolish Shc threonine
phosphorylation. All proteins tested were able to pull-down Shc (Figure 14). Nedd4 binds

to Shc constitutively which suggests that the interaction is driven by the proline-rich

motifs within the CH1 domain of Shc rather than phosphorylation (Figure 14B).

Interestingly, while all three 14-3-3 isoforms could bind to Shc in an EGF stimulationdependent manner, they were differentially affected by Erk activity. When Erk activity is

inhibited, the ζ isoform interaction with Shc is reduced, whereas the binding between Shc
and 14-3-3 τ increased and its binding with 14-3-3 ε remain unchanged (Figure 14C and

D). The sequences of the three 14-3-3 isoforms are highly conserved, it would therefore
be interesting to find out how they are able to bind differently to Shc. Another notable

feature is that the 14-3-3 proteins preferentially bind to the p52 rather than the p46
isoforms, even though the phosphothreonine sites are identical. This suggests that the N-

terminal sequence on p52 play a role in stabilizing the interaction. 14-3-3 ζ has been

previously reported to upregulate PI3K signaling when recruited to Shc, it is therefore

likely that threonine-phosphorylated Shc augments Akt phosphorylation by interacting
with 14-3-3 ζ [96,167]. Finally, Pin1 interacts with Shc when cells are stimulated with EGF
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and the binding is abolished when Erk activity is inhibited. This is consistent with the fact
that Pin1 binding and activity are pT/pS-dependent. As expected, C113A mutation in Pin1

did not affect its binding to Shc as this mutation has been shown to affect isomerase
activity without altering its phosphothreonine binding ability [168].

Since Pin1 is critical in oncogenesis [169,170] and is overexpressed in the MDA-MB-

468 cell line [171], we tested to see if binding between Shc and Pin1 is indeed direct. We
purified both recombinant Shc and Pin1 from E. coli. and performed a pull-down

experiment through the His-tag on Shc. Shc was also preincubated with Erk in the

presence or absence of ATP and MgCl2 to verify that threonine phosphorylation is critical
to the interaction.

To our surprise Erk-mediated phosphorylation is only partially

responsible for Shc and Pin1 binding. One possible explanation is that the Pin1 WW

domain can also interact with proline-rich motifs and ShcCH1 contains several such motifs.

The inconsistent results obtained from the pull-down experiments using cell lysates and
purified protein could be due to competing binding partners that exist in the cell lysates.
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Figure 14. Pull-down experiments to identify Shc protein binding partners that are
affected by Shc threonine phosphorylation. MDA-MB-468 cells were starved overnight

and then stimulated with 20ng/ml EGF for 5 minutes with or without pre-incubation with

10μM of the Mek inhibitor U0126. (A) Erk was effectively inhibited by U0126 as shown by
immunoblotting for phospho-Erk1/2.

(B) to (E) Fusion proteins were purified and

immobilized on agarose beads and incubated with MDA-MB-468 lysates overnight. Beads
were washed with lysis buffer and the samples were analyzed by western blotting for the
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presence of Shc. (B) HA-tagged Nedd4 (C) GFP-14-3-3 ζ (D) GST-14-3-3 τ and GST 14-3-3

ε (E) GST-Pin1 WT or C113A (F) Recombinant His-tagged p52 Shc and Pin1 were purified
from E. coli.

Shc was phosphorylated by active Erk2.

After the removal of Erk2,

immobilized Shc was incubated with Pin1. The direct binding of Shc and Pin1 was
confirmed by western blotting (left panel). Shc is phosphorylated by Erk on threonine
residues (right panel).

4.3 Discussion
Although it is clear that serine/threonine phosphorylation on scaffold molecules

function as feedback events in RTK signaling, the molecular mechanism of how this occurs
is less so. In this Chapter, we show upon activation of EGFR, Erk phosphorylates Shc on

three residues which leads to elevated Erk and Akt phosphorylation in the HEK293T in an

in vitro system. This suggests that phosphorylation of Shc on threonine residues mediates
a positive feedback loop in Erk-signaling and crosstalk between the Erk and Akt pathways.

Furthermore, we found that in two triple-negative breast cancer cell lines, MDA-MB-468

and MDA-MB-231, Shc exhibits a significant level of phosphorylation on T214 but not in
the non-transformed MCF10A cell line. This suggests phosphorylation of Shc on threonine

residues is involved in breast cancer oncogenesis, which is in line with the observation of
the upregulation of Erk and Akt phosphorylation in the HEK293T in vitro system.

To understand how threonine phosphorylation augments downstream signaling,

we explored two possibilities. First, we investigated whether threonine phosphorylation
affects Shc overall conformation. This is because two of the phosphorylation sites reside
in the disordered CH1 domain. Intrinsically disordered regions on proteins allow for
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many transient conformations which are important for regulating dynamics in signaling by

altering protein recruitment and affecting the accessibility for kinases and/or
phosphatases. By changing the charges of these intrinsically disordered regions,

phosphorylation is particularly important in shifting the equilibrium of conformations

[172]. However, using a number of biochemical and biophysical techniques, we failed to
detect any significant conformational changes in Shc.

Second, we examined whether the formation of these new phospho-motifs alters

protein recruitment. Several domains are well-characterized for their abilities to bind to

pS/pT residues, for example the WW-domain and 14-3-3 proteins [160]. We identified
three proteins whose binding to Shc is pT-dependent: GAPDH, Pin1 and 14-3-3 ζ. Previous

reports show that 14-3-3 ζ binding to the SH2 domain of Shc to be mediated by the

phosphorylation of 14-3-3 ζ on tyrosine 179 which leads to upregulation in PI3K and
subsequently AKT signaling [68,96]. Our data suggest an additional mechanism for this

interaction whereby 14-3-3 ζ binds to threonine phosphorylated Shc. This is not surprising
given that 14-3-3 proteins are known for their roles in binding to pS/pT. 14-3-3 ζ

structure shows the pS residue lies within the binding pocket for pS/pT motifs in the
protein (PDB: 4HKC). T407 also resides in the pY-binding pocket of ShcSH2 (PDB: 1TCE).

Hence, there is a possibility that simultaneous phosphorylation on both 14-3-3 ζ and

ShcSH2 enhance the interaction of the two proteins (Figure 15). As discussed in Chapter 1,
recruitment of 14-3-3 ζ to Shc has been shown to increase PI3K signaling. Given that PI3K

is an upstream activator of Akt, it seems likely that this interaction is at least partially
responsible for the elevated pAkt level seen in TEShc cells.

117

Figure 15. Structures of 14-3-3 ζ and ShcSH2. A) 14-3-3 ζ (purple) in complex

with a phosphoserine-containing peptide (blue) derived from the integrin receptor (PDB:
4HKC).

Phosphorylated serine on integrin peptide and tyrosine 179 on 14-3-3 ζ are

highlighted as sticks models. Y179 is faces towards the phosphoserine-binding pocket in
14-3-3 ζ.

B) ShcSH2 (orange) in complex with phosphotyrosine-containing peptide

(yellow) derived from the T-cell receptor (PDB: 1TCE).

T407 on ShcSH2 and

phosphorylated tyrosine on T-cell peptide are highlighted as sticks models. T407 is in
close proximity to the phosphotyrosine-binding pocket of ShcSH2.

Pin1 has previously been shown to recruit p66Shc to the mitochondria in a PKC-

dependent manner, which is a process that leads to apoptosis [54]. Here we show that
p52Shc can also bind to Pin1, albeit through different phospho-residues. However, the

role for this interaction is unclear and requires further investigation. Some peptide prolyl
cis-trans isomerases (PPIases), such as Pin1 specifically catalyzes proline residues

preceded by pS/pT. PPIases catalyzes the conversion of cis-trans conformation of proline
which can potentially switch local conformations from one to another [170] and adjust

protein-recruitment profiles. In addition, because some phosphatases only act on certain

phospho-isoforms, such as PP2A [173], proline-isomerization can also alter the rate of
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phosphorylation/dephosphorylation [170]. We have previously identified another PPIase,

cyclophilin A (CypA) as a direct binding partner for Shc [25]. Given that ShcCH1 is prolinerich, it is likely that Shc is regulated by proline isomerization. This would form an

interesting direction for future investigation into Shc signaling in addition to the better
characterized PTMs.

Finally, p66Shc has recently been reported to regulate glycolysis indirectly through

the inhibition of mTOR signaling [70]. It would be interesting to see if p52Shc plays a
direct role in glycolytic flux through the phosphothreonine-dependent recruitment of
GAPDH.

Another important point that requires further investigation is the importance of the

individual phosphorylation sites. While in the in vitro systems such as the 293T phosphomutants cell lines and the recombinantly expressed and purified Shc proteins examine the
effects of all three sites together, whether endogenous Shc is phosphorylated on all three

sites in cellular environment and their individual contributions to downstream signaling
require further characterization.

We have been unable to examine the endogenous

phosphorylation levels of Shc T276 and T407 due to the lack of specific antibodies.
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Chapter 5

Discussion
Deciphering cellular signaling networks is vital to our understanding of how

external inputs are translated into appropriate phenotypic outputs through the
intracellular environment. At the protein level the combinatorial use of protein domains

and post-translational modifications are important strategies in generating signaling
networks. In this thesis, I examined the multifaceted role of the scaffold protein Shc in Erk
signaling both prior to and post-growth factor stimulation via two strategies.

First, I

described a novel role for Shc in Erk inhibition prior to growth factor stimulation through

the PTB domain of Shc in Chapter 3. Second, I investigated how Erk-mediated Shc

phosphorylation after stimulation regulates signaling feedback and crosstalk in Chapter 4.

I demonstrate that in the absence of extracellular stimulation, Shc and Erk associate

via a novel interface using the α2-β3 loop in ShcPTB and N-terminal lobe in Erk (Chapter 3,
Figure 6). This association is inhibitory to Erk phosphorylation and restricts Erk in the
cytoplasm.

Upon EGF stimulation, Shc contributes towards an initial phase of Erk

activation by 1) binding to activated RTKs which triggers the release of Erk through an

allosteric mechanism and 2) the recruitment of Grb2-Sos complex to the plasma
membrane, which is well established in previous research.

Activated Erk in turn

phosphorylates Shc on three threonine residues. These phosphothreonines subsequently
mediate 1) a positive feed-forward loop in sustaining Erk activity and 2) crosstalk with Akt
signaling, possibly through the recruitment of 14-3-3 ζ (Figure 1).
sections, I discuss the potential roles of these findings.
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In the following

5.1 Signaling
Protein complexes can be generated by the specific binding between a folded

domain on one protein and a short motif on another [10,15]. One such folded domain is

the phosphotyrosine-binding (PTB) domain. The core PTB fold contains two orthogonal
anti-parallel β-sheets capped by a C-terminal α-helix, which enables this class of protein

domain to bind to NPXY motifs. While all PTB domains contain this core fold, the loop
responsible for binding to Erk in ShcPTB is unique to Shc [174]. Hence, this mode of

interaction with Erk could be unique to the Shc family among the PTB-containing proteins.

This suggests the diversity that exists outside the conserved polypeptide fold within a
single class of protein domain can also be used to mediate specific protein-protein
interactions. Along the same line, another example for non-canonical binding in the PTB

domain family is Frs2. In addition to the core PTB-fold which enables the domain to

recognize the NPXY consensus sequence, it contains an extra β-sheet which allows it to
bind to a VTVS sequence on FGF receptors [175].

Analysis of Erk interacting partners by von Kriegsheim et. al. [7] indicated that a

number of proteins, such as RSK and NF1, associate with Erk prior to growth factor
stimulation. Similar to Shc, these proteins also release Erk post-stimulation. It will be

interesting to investigate whether conformational changes in these proteins also trigger
the release of Erk, much as we identified with Shc in this work.

Both Shc and Erk have been shown to regulate the signaling initiated by numerous

growth factors. While this study focuses on EGF stimulation, it will be interesting to find
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out if other growth factors would lead to the dissociation of the Shc-Erk complex and

phosphorylation of Shc by Erk. More importantly, can the interaction between Shc and Erk
contribute towards the differences in signaling transmitted by different RTKs?

For

example, the NGF receptor TrkA contains only one binding site for ShcPTB [176], whereas
EGFR contains two [177]. Would the difference in the number of Shc molecules recruited

to a RTK be translated into the number of Erk molecules released and hence signal
strength? Also, how would the duration of Erk activation, a property that is dependent on
which RTK is stimulated and cell type, affect Shc threonine phosphorylation and Shcmediated crosstalk with the Akt pathway?
5.2 Development
The role of Shc in Erk signaling through the recruitment of Grb2 (which is

dependent on the phosphorylation on Y239/240/317 of Shc) was explored in the

development of cardiovascular, muscles, immune and neuronal systems (Section 1.5). In
all cases, there are differences in the phenotypic outcome between Shc-null and Shc

Y239/240/317F mutants. This indicates that in addition to the recruitment of Grb2, Shc
functions in these developmental systems via mechanisms that are independent of the

Shc-Grb2 axis. It would therefore be interesting to investigate the importance of the novel

interactions that we have identified in this thesis in developmental systems. For example,
in the neuronal system, microencephaly was observed in both Shc-null and
Y239/240/317F animals. However, the molecular basis for this phenotype mediated by
the two genotypes is different. The subventricular zone of the brain in the Shc-null
animals showed a reduction in cell proliferation, whereas Y239/240/317F animals

exhibited an increased in apoptosis. Since cell proliferation and apoptosis are associated
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with Erk and Akt signaling respectively, it seems likely that Y239/240/317
phosphorylation in the neuronal system mediates cell survival through binding to Grb2

and its subsequent recruitment of the p85 subunit of PI3K which then in turn activates Akt
(Section 1.4.2). In contrast, since cell proliferation was not affected in the Y239/240/317F

animals, cell proliferation as a result of Erk signaling would be mediated by a Grb2-

independent mechanism in the Shc-null animals. The direct interaction between Shc and

Erk, as well as Shc threonine phosphorylation by Erk regulates Erk activity independent of
Grb2, hence we speculate that the novel mechanisms described in this thesis between Shc
and Erk play important roles in Erk signaling in the development of the neuronal system.

The same argument is true for the development of the cardiovascular system. Deleting
ShcA in mice causes embryonic lethality due to abnormality in the heart. However,
Y239/240/317F mutant animals are viable with grossly normal cardiovascular structures,

suggesting that the cardiovascular defects seen in ShcA-null animals are not due to the

phosphorylation of Y239/240/317. Interestingly, experiments in MEFs obtained from the

Shc-null embryos suggest that Erk signaling is affected by the removal of Shc, as Shc was
required for Erk phosphorylation when cells were exposed to a low level of growth factors.

Again, this indicates that Shc regulates Erk signaling through a Grb2-independent

mechanism.

Both Shc-Erk direct binding and pT Shc are likely to be important in

potentiating Erk activity. This is because at a low growth factor level, a relatively small

number of RTK would be activated and subsequently phosphotyrosine-mediated signaling
would be limited. The higher phospho-Erk level seen in WT compared with Shc-null MEFs

under such condition is probably caused by 1) an increase in ‘free’ Erk available for
activation driven by the dissociation of Shc-Erk complex and 2) the positive feedback in
Erk activation mediated by threonine phosphorylated Shc.
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Furthermore, even though we did not find a direct relationship between the

phosphorylation of Y239/240/317 and T214/276/407 on Shc, the overall Erk activity

would be a combined effect of both types of phosphorylation events. Hence, it would be
interesting

to

delineate

the

effects

of

T214/276/407

phosphorylation

from

Y239/240/317 phosphorylation, such as by the use of Shc T214/276/407A mutant
animals. Since T214/276/407 seems to be important in the temporal regulation of Erk

phosphorylation, rather than function as an ‘on’ switch for Erk activity in the HEK293T in
vitro system, investigating the role of T214/276/407 in developmental systems might
shed light in the importance of temporal regulation of Erk in such systems.
5.3 Disease
As discussed in Section 1.6.2, even though Shc plays critical roles in the

pathogenesis of breast cancer, it does not seem to function through the upregulation of Erk

activity. Instead, Shc augments Akt signaling to mediate cell survival via the recruitment
of 14-3-3 ζ using ShcSH2. Previous work shows that the interaction between 14-3-3 ζ and

the Shc SH2 domain is mediated by the tyrosine phosphorylation of 14-3-3 ζ. Here, we

show that Shc recruits 14-3-3 ζ when Shc is threonine phosphorylated and that Akt

signaling is upregulated in the presence of the Shc phosphothreonine (TEShc) mutant.

Taken together, our data suggests that Shc threonine phosphorylation augments Akt
signaling through the recruitment of 14-3-3 ζ. This interaction would have important
implications in oncogenesis.

This work presents two potential avenues for therapeutic intervention in diseases

driven by Erk activity. First, we can exploit the knowledge of the Shc-Erk dissociation
mechanism to obtain small molecules that would block the binding of RTK without
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triggering a conformation change in Shc to stabilize the Shc-Erk complex. Such small

molecules could be useful in diseases caused by over-active Erk cascade with Shc
overexpression.

In this scenario, the small molecule would serve two functions: 1)

blockade of RTK-Shc interaction. This would lead to a lack of Shc tyrosine phosphorylation
by RTK and hence Shc-Grb2/Sos interaction and the subsequent activation of the Erk

cascade; 2) Shc would be trapped in a conformation that can ‘mop-up’ Erk by direct
binding. The usefulness of such small molecules is supported by a recent mouse study
which shows that disabling ShcPTB signaling can lead to delayed tumor onset [98].

Second, the Shc threonine phosphorylation sites could potentially serve as markers

for erroneous Erk and Akt signaling in TNBC with EGF receptor overexpression. The two
TNBC cell lines in which we found pT214 to be significantly phosphorylated both contain

an overexpression of EGFR [178,179]. While TNBC describes a collection of disease with
highly variable genotypes, some can be sub-grouped by their EGF receptor expression

status [180,181]. To explore the role of Shc threonine phosphorylation in TNBC, we can

perform IHC analysis for pT Shc level on patient tumor samples and correlate clinical
outcome, such as stage of disease and disease-free survival.

To investigate if our

observations that threonine phosphorylation of Shc on T214/276/407 upregulates Erk

and Akt signaling, we can also correlate pT Shc level with pErk and pAkt levels using IHC
of cancer patient samples.
5.4 Summary
Using a quantitative proteomics approach, Zheng et. al. comprehensively described

the temporal contribution of Shc in the EGFR pathway. Shc was found to associate with

distinct sets of proteins and to be phosphorylated at multiple sites at specific time-points
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post-EGF stimulation [26], revealing that versatility in Shc-mediated protein-protein
interaction is required to regulate EGF signaling.

The present study of the relationship

between Shc and Erk illustrates the degree of complexity a single signaling axis can reach.

A phenotypic output is thus the result of compounded effects of multiple relationships
between any two signaling molecules.

Combined with the recent advances in high-

throughput screening of protein complexes [182,183,184] and computational analysis of

protein interactome [185,186], the ability to elucidate finer details of how proteins

interact as exemplified by the present work will lead to the development of therapeutic
strategies that can target important nodes in signaling networks of human disease
[187,188,189].
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Figure 1 Summary of the mutual
regulation between Shc and Erk. 1.

In

the

absence

of

extracellular

stimulation, Shc and Erk forms a

complex via a novel binding interface.

2. Upon EGF stimulation, Shc binds to
the activated EGF receptor, which

triggers a conformational change in
Shc and leads to Erk dissociation
from the complex.

3.

Shc is

phosphorylated by the receptor on its
tyrosine residues, which recruits the

Grb2-Sos complex to the membrane.

This activates Ras, which initiates the
activation of the Erk cascade.

4.

Activated Erk phosphorylates Shc on

threonine residues, which further

elevates the Erk phosphorylation and

activate Akt, possibly through the
recruitment
complex.
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